{"content":"<li class=\"n-box-item date-title\" data-end=\"1537847999\" data-start=\"1537761600\" data-txt=\"Monday, December 23, 2019\">Monday, September 24, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3392598\" data-ts=\"1537829746\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ST\" target=\"_blank\">ST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392598-sensata-to-acquire-gigavac-for-233m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sensata to acquire GIGAVAC for $233M</a></h4><ul>   <li>Sensata Technologies (NYSE:<a href='https://seekingalpha.com/symbol/ST' title='Sensata Technologies Holding N.V.'>ST</a>) has a deal to <a href=\"https://seekingalpha.com/pr/17279153-sensata-technologies-strengthens-position-electrification-acquisition-gigavac\" target=\"_blank\">acquire privately held GIGAVAC</a> for about $233M in cash.</li>    <li>Adding the new portfolio will allow Sensata to tap a $1B market for high-voltage contractors called for in products including cars, delivery trucks, buses, material handling equipment and charging stations.</li>    <li>&ldquo;Over the past four months, we have significantly strengthened Sensata&rsquo;s overall portfolio by divesting our lower growth valves business, and acquiring a fast-growing, highly differentiated business in GIGAVAC,&rdquo; says CEO Martha Sullivan.</li>    <li>GIGAVAC revenues have grown at a compound annual rate of more than 30% in five years, and it expects to log $80M in revenues for 2018.</li>    <li>The deal's expected to be slightly accretive to Sensata's fiscal 2019 EPS; it expects to close in Q4.</li>    <li>Sensata shares are <font color='green'>up 2.3%</font> in after-hours trading.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392598\" data-linked=\"Sensata to acquire GIGAVAC for $233M\" data-tweet=\"$ST - Sensata to acquire GIGAVAC for $233M https://seekingalpha.com/news/3392598-sensata-to-acquire-gigavac-for-233m?source=tweet\" data-url=\"https://seekingalpha.com/news/3392598-sensata-to-acquire-gigavac-for-233m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392591\" data-ts=\"1537825923\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VLY\" target=\"_blank\">VLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392591-valley-national-moving-listing-to-nasdaq-sharesplus-2_2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Valley National moving listing to Nasdaq; shares +2.2%</a></h4><ul>   <li>Valley National Bancorp (NASDAQ:<a href='https://seekingalpha.com/symbol/VLY' title='Valley National Bancorp'>VLY</a>) is <font color='green'>up 2.2%</font> after hours, rebounding from a decline today, following news that it's <a href=\"https://seekingalpha.com/pr/17279165-valley-national-bancorp-announces-transfer-stock-listing-nasdaq\" target=\"_blank\">transferring its stock listing to Nasdaq</a>, from NYSE.</li>    <li>It will continue to be listed under the same symbol.</li>    <li>Preferred A stock will list under the symbol VLYPA, preferred B stock under VLYPB, and warrants under <a href='https://seekingalpha.com/symbol/VLYWW' title='Valley National Bancorp Warrants 2010-14.11.18 on Shs'>VLYWW</a>.</li>    <li>\"We are excited by our future partnership with Nasdaq,\" says CEO Ira Robbins. \"Their trading platform and marketing initiatives offer Valley the most cost-effective listing option and are aligned with our goals to enhance operating efficiencies.\"</li>    <li>Shares had <font color='red'>fallen 2.2%</font> during the regular session today.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392591\" data-linked=\"Valley National moving listing to Nasdaq; shares +2.2%\" data-tweet=\"$VLY - Valley National moving listing to Nasdaq; shares +2.2% https://seekingalpha.com/news/3392591-valley-national-moving-listing-to-nasdaq-sharesplus-2_2?source=tweet\" data-url=\"https://seekingalpha.com/news/3392591-valley-national-moving-listing-to-nasdaq-sharesplus-2_2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392589\" data-ts=\"1537825277\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASNA\" target=\"_blank\">ASNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392589-after-hours-gainers-losers-09-24-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (09/24/2018)</a></h4><ul><li><b>Top Gainers:</b> <a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group Inc'>ASNA</a> <font color='green'>+9.2%</font>. <a href='https://seekingalpha.com/symbol/BAS' title='Basic Energy Services, Inc.'>BAS</a> <font color='green'>+6.5%</font>. <a href='https://seekingalpha.com/symbol/AWX' title='Avalon Holdings Corporation'>AWX</a> <font color='green'>+4.3%</font>. <a href='https://seekingalpha.com/symbol/JONE' title='Jones Energy, Inc.'>OTC:JONE</a> <font color='green'>+3.4%</font>. <a href='https://seekingalpha.com/symbol/FTCH' title='Farfetch'>FTCH</a>&nbsp;<font color='green'>+2.4%</font>.</li><li><b>Top Losers:</b> <a href='https://seekingalpha.com/symbol/GEMP' title='Gemphire Therapeutics'>GEMP</a> <font color='red'>-5.6%</font>. <a href='https://seekingalpha.com/symbol/CTL' title='CenturyLink, Inc.'>CTL</a> <font color='red'>-4.6%</font>. <a href='https://seekingalpha.com/symbol/BJ' title='BJ&#39;s Wholesale Club, Inc.'>BJ</a>&nbsp;<font color='red'>-2.7%.</font>&nbsp;<a href='https://seekingalpha.com/symbol/DCPH' title='Deciphera Pharmaceuticals, Inc.'>DCPH</a> <font color='red'>-2.4%</font>. <a href='https://seekingalpha.com/symbol/DQ' title='DAQO New Energy Corp.'>DQ</a> <font color='red'>-2.4%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392589\" data-linked=\"After Hours Gainers / Losers (09/24/2018)\" data-tweet=\"$ASNA $ASNA $BAS - After Hours Gainers / Losers (09/24/2018) https://seekingalpha.com/news/3392589-after-hours-gainers-losers-09-24-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3392589-after-hours-gainers-losers-09-24-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392587\" data-ts=\"1537824798\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAS\" target=\"_blank\">BAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392587-key-energy-offers-all-stock-merger-deal-basic-energy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Key Energy offers all-stock merger deal with Basic Energy</a></h4><ul>     <li>Basic Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/BAS' title='Basic Energy Services, Inc.'>BAS</a>)&nbsp;<font color='green'>+6.7%</font> after-hours as Key Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/KEG' title='Key Energy Services, Inc.'>KEG</a>) <a href=\"https://seekingalpha.com/pr/17279121-key-energy-services-inc-proposes-combination-basic-energy-services-inc-stock-transaction\" target=\"_blank\">proposes an all-stock merger</a> at a fixed exchange ratio of 0.733x shares of KEG for each share of BAS.</li>     <li>Under the deal terms, KEG shareholders would own  ~51% of the combined company and BAS shareholders would  own 49%, which KEG says represents a 15% premium to BAS's share price based on the volume-weighted average closing price of the preceding 10 market sessions.</li><li>KEG says the pro forma combined company would have estimated 2019 revenue of $1.8B and EBITDA of  more than $275M, including the impact of estimated  synergies, with a run-rate of $65M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392587\" data-linked=\"Key Energy offers all-stock merger deal with Basic Energy\" data-tweet=\"$BAS $BAS $KEG - Key Energy offers all-stock merger deal with Basic Energy https://seekingalpha.com/news/3392587-key-energy-offers-all-stock-merger-deal-basic-energy?source=tweet\" data-url=\"https://seekingalpha.com/news/3392587-key-energy-offers-all-stock-merger-deal-basic-energy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392585\" data-ts=\"1537824297\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DCPH\" target=\"_blank\">DCPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392585-decipheraminus-2_4-leerink-sees-30-downside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deciphera -2.4% as Leerink sees 30% downside</a></h4><ul>   <li>Deciphera Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DCPH' title='Deciphera Pharmaceuticals, Inc.'>DCPH</a>) is <font color='red'>2.4% lower</font> after hours following an initiation at Underperform by Leerink Partners.</li>    <li>The firm set its price target to $28, implying 30% downside from today's close.</li>    <li>Shares had <font color='green'>risen 2.4%</font> during today's regular session.</li>    <li><a href='https://seekingalpha.com/symbol/DCPH' title='Deciphera Pharmaceuticals, Inc.'>DCPH</a> is <font color='green'>up 90.9%</font> over the past six months.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392585\" data-linked=\"Deciphera -2.4% as Leerink sees 30% downside\" data-tweet=\"$DCPH - Deciphera -2.4% as Leerink sees 30% downside https://seekingalpha.com/news/3392585-decipheraminus-2_4-leerink-sees-30-downside?source=tweet\" data-url=\"https://seekingalpha.com/news/3392585-decipheraminus-2_4-leerink-sees-30-downside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392583\" data-ts=\"1537823850\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSTI\" target=\"_blank\">PSTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392583-pluristemplus-3_1-wins-orphan-drug-designation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pluristem +3.1% as it wins orphan drug designation</a></h4><ul>   <li>Pluristem Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PSTI' title='Pluristem Therapeutics, Inc.'>PSTI</a>) is <font color='green'>up 3.1%</font> after hours following an FDA <a href=\"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=626418\" target=\"_blank\">orphan drug designation</a> for its ex-vivo expanded placental adherent stromal cells.</li>    <li>The treatment was designated for treating graft failure and incomplete hematopoietic recovery after hematopoietic cell transplantation.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392583\" data-linked=\"Pluristem +3.1% as it wins orphan drug designation\" data-tweet=\"$PSTI - Pluristem +3.1% as it wins orphan drug designation https://seekingalpha.com/news/3392583-pluristemplus-3_1-wins-orphan-drug-designation?source=tweet\" data-url=\"https://seekingalpha.com/news/3392583-pluristemplus-3_1-wins-orphan-drug-designation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392579\" data-ts=\"1537822643\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNDX\" target=\"_blank\">SNDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392579-syndax-pharma-down-12-after-hours-on-updated-mid-stage-data-on-entinostat-pembrolizumab-combo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Syndax Pharma down 12% after hours on updated mid-stage data on entinostat/pembrolizumab combo in lung cancer</a></h4><ul><li>Thinly traded micro cap Syndax Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SNDX' title='Syndax Pharmaceuticals, Inc.'>SNDX</a>) slumps&nbsp;<font color='red'>12%</font>&nbsp;after hours following its <a href=\"https://seekingalpha.com/pr/17279023-syndax-announces-updated-results-phase-2-encore-601-trial-entinostat-combination-keytruda\" target=\"_blank\">announcement</a> of updated data from the Phase 2 ENCORE 601 study evaluating entinostat + Merck's Keytruda (pembrolizumab) in patients with non-small cell lung cancer &#40;NSCLC&#41; who have been treated previously with both chemo and a PD-1 (or L1) inhibitor. The results were presented at the World Conference on Lung Cancer in Toronto.</li><li>Data from 72 evaluable patients showed a 10% objective response rate, all partials. Median duration of response was 5.3 months and median progression-free survival &#40;PFS&#41; was 2.8 months. The overall survival endpoint was not met.</li><li>Separately, enrollment in the Phase 3 E2112 study evaluating entinostat plus exemestane in patients with advanced HR+/HER2- breast cancer is now expected to close in late October . PFS data should be announced in Q4.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3357672-syndax-22-percent-mid-stage-entinostat-data\" target=\"_blank\">Syndax down 22% on mid-stage entinostat data</a> (May 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392579\" data-linked=\"Syndax Pharma down 12% after hours on updated mid-stage data on entinostat/pembrolizumab combo in lung cancer\" data-tweet=\"$SNDX - Syndax Pharma down 12% after hours on updated mid-stage data on entinostat/pembrolizumab combo in lung cancer https://seekingalpha.com/news/3392579-syndax-pharma-down-12-after-hours-on-updated-mid-stage-data-on-entinostat-pembrolizumab-combo?source=tweet\" data-url=\"https://seekingalpha.com/news/3392579-syndax-pharma-down-12-after-hours-on-updated-mid-stage-data-on-entinostat-pembrolizumab-combo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392576\" data-ts=\"1537822285\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DAC\" target=\"_blank\">DAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392576-danaos-beats-0_04-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Danaos beats by $0.04, beats on revenue</a></h4><ul><li>Danaos (NYSE:<a href='https://seekingalpha.com/symbol/DAC' title='Danaos Corporation'>DAC</a>): Q2 Non-GAAP EPS of $0.27 <span style=\"color:green\">beats by $0.04</span>; GAAP EPS of $0.05.</li><li>Revenue of $113.47M (-0.4% Y/Y) <font color='green'>beats by $6.23M</font>.</li><li>Shares <font color='green'>+9.09%</font>.</li><li><a href='https://seekingalpha.com/pr/17279113-danaos-corporation-reports-second-quarter-half-year-results-period-ended-june-30-2018'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3392576\" data-linked=\"Danaos beats by $0.04, beats on revenue\" data-tweet=\"$DAC - Danaos beats by $0.04, beats on revenue https://seekingalpha.com/news/3392576-danaos-beats-0_04-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3392576-danaos-beats-0_04-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392568\" data-ts=\"1537821520\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARNA\" target=\"_blank\">ARNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392568-arena-pharma-up-3-after-hours-on-positive-olorinab-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arena Pharma up 3% after hours on positive olorinab data</a></h4><ul><li>Arena Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ARNA' title='Arena Pharmaceuticals, Inc.'>ARNA</a>) is up&nbsp;<font color='green'>3%</font>&nbsp;after hours in response to its <a href=\"https://seekingalpha.com/pr/17279006-arena-pharmaceuticals-reports-positive-phase-2a-results-olorinab-patients-abdominal-pain\" target=\"_blank\">announcement </a>of positive topline results from a Phase 2a clinical trial evaluating olorinab, a cannabinoid receptor 2 agonist, for the treatment of gastrointestinal pain associated with quiescent to mildly active Crohn's disease.</li><li>14 patients were enrolled with a mean baseline Average Abdominal Pain Score &#40;AAPS&#41; of at least 5.6 (AAPS score of at least 4.0 needed to meet diagnostic criteria). In 11 evaluable patients at week 8 (baseline AAPS of 6.0), there was an improvement in AAPS of -4.6 from baseline at peak effect (1.5 hours post morning dose).</li><li>At peak effect, 85% (n=11/13) of evaluable patients at week 4 and 100% (n=11/11) evaluable patients at week 8 showed clinically relevant improvement in AAPS. The improvement in pain was consistent at both the 25 mg and 100 mg doses. A statistically significant improvement in AAPS was also seen at trough levels (before the morning dose).</li><li>On the safety front, olorinab was generally well-tolerated with no new safety signals observed. There were no discontinuations due to adverse events.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392568\" data-linked=\"Arena Pharma up 3% after hours on positive olorinab data\" data-tweet=\"$ARNA - Arena Pharma up 3% after hours on positive olorinab data https://seekingalpha.com/news/3392568-arena-pharma-up-3-after-hours-on-positive-olorinab-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3392568-arena-pharma-up-3-after-hours-on-positive-olorinab-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392566\" data-ts=\"1537821371\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNP\" target=\"_blank\">CNP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392566-centerpoint-energy-launches-concurrent-public-offerings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CenterPoint Energy launches concurrent public offerings</a></h4><ul>     <li>CenterPoint Energy (NYSE:<a href='https://seekingalpha.com/symbol/CNP' title='CenterPoint Energy, Inc.'>CNP</a>) <font color='red'>-4.5%</font> after-hours as it commences <a href=\"https://seekingalpha.com/pr/17279024-centerpoint-energy-announces-concurrent-public-offerings-1_50-billion-common-stock-0_75\" target=\"_blank\">concurrent public offerings</a> of $1.5B in common shares and $750M in depositary shares, with an underwriters option to purchase up to an additional $225M of common shares and up to an additional 2.25M depositary shares.</li>     <li>CNP says it plans to use the net proceeds to finance part of the cash consideration in its pending merger with Vectren (NYSE:<a href='https://seekingalpha.com/symbol/VVC' title='Vectren Corp'>VVC</a>).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392566\" data-linked=\"CenterPoint Energy launches concurrent public offerings\" data-tweet=\"$CNP $CNP $VVC - CenterPoint Energy launches concurrent public offerings https://seekingalpha.com/news/3392566-centerpoint-energy-launches-concurrent-public-offerings?source=tweet\" data-url=\"https://seekingalpha.com/news/3392566-centerpoint-energy-launches-concurrent-public-offerings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392565\" data-ts=\"1537821197\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASNA\" target=\"_blank\">ASNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392565-ascena-retail-rallies-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ascena Retail rallies after earnings</a></h4><ul> <li>Ascena Retail Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group Inc'>ASNA</a>) is higher in AH trading after topping FQ4 expectations and setting pleasing guidance.</li> <li>The company guides for FY19 revenue of $6.45B to $6.55B vs. $6.22B consensus and FY19 EPS of $0.00 to $0.10 vs. $0.08 consensus.</li> <li>Ascena says it's on track to hit its annual run rate savings target of $300M by July of 2019.</li><li>ASNA <font color='green'>+9.73%</font> AH to $4.40.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392565\" data-linked=\"Ascena Retail rallies after earnings\" data-tweet=\"$ASNA - Ascena Retail rallies after earnings https://seekingalpha.com/news/3392565-ascena-retail-rallies-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3392565-ascena-retail-rallies-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392562\" data-ts=\"1537821012\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTL\" target=\"_blank\">CTL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392562-centurylinkminus-3_8-cfo-patel-to-exit-post-for-t-mobile\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CenturyLink -3.8% as CFO Patel to exit post for T-Mobile</a></h4><ul>    <li>CenturyLink (NYSE:<a href='https://seekingalpha.com/symbol/CTL' title='CenturyLink, Inc.'>CTL</a>) is <font color='red'>3.8% lower</font> after hours, following news Chief Financial Officer Sunit Patel is <a href=\"https://seekingalpha.com/pr/17279059-centurylink-chief-financial-officer-sunit-patel-depart-company\" target=\"_blank\">departing the company</a> after taking a leadership role elsewhere.</li>    <li>The resignation is effective Sept. 28.</li>    <li>Neel Dev, the company's VP of finance, will take over as interim CFO; he was integration planning lead for the Level 3 acquisition and has been part of Patel's leadership team for 14 years.</li><li>CenturyLink says they'll consider internal and external candidates for the permanent replacement.</li>    <li><b>Updated 4:33 p.m.:</b> Patel is <a href=\"https://seekingalpha.com/pr/17279069-t-mobile-us-names-sunit-patel-new-evp-merger-integration-lead\" target=\"_blank\">joining T-Mobile</a> (NASDAQ:<a href='https://seekingalpha.com/symbol/TMUS' title='T-Mobile US, Inc.'>TMUS</a>) as its new executive VP, Merger and Integration Lead, effective Oct. 1. He'll lead strategic planning on an integration with Sprint (NYSE:<a href='https://seekingalpha.com/symbol/S' title='Sprint Corporation'>S</a>).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392562\" data-linked=\"CenturyLink -3.8% as CFO Patel to exit post for T-Mobile\" data-tweet=\"$CTL $CTL $TMUS - CenturyLink -3.8% as CFO Patel to exit post for T-Mobile https://seekingalpha.com/news/3392562-centurylinkminus-3_8-cfo-patel-to-exit-post-for-t-mobile?source=tweet\" data-url=\"https://seekingalpha.com/news/3392562-centurylinkminus-3_8-cfo-patel-to-exit-post-for-t-mobile\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>106&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392554\" data-ts=\"1537820191\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PETQ\" target=\"_blank\">PETQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392554-petiq-readies-stock-offering-shares-down-3-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PetIQ readies stock offering; shares down 3% after hours</a></h4><ul><li>PetIQ (NASDAQ:<a href='https://seekingalpha.com/symbol/PETQ' title='PetIQ'>PETQ</a>) <a href=\"https://seekingalpha.com/pr/17279005-petiq-inc-announces-public-offering-common-stock\" target=\"_blank\">commences </a>a public offering of 8M shares of stock, 2M Class A shares from the company and 3M Class A and 3M Class B shares from existing investors. Selling shareholders will also offer underwriters an over-allotment of up to 750K additional Class A shares. Pricing and terms have yet to be determined.</li><li>Shares are down&nbsp;<font color='red'>3%</font>&nbsp;after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392554\" data-linked=\"PetIQ readies stock offering; shares down 3% after hours\" data-tweet=\"$PETQ - PetIQ readies stock offering; shares down 3% after hours https://seekingalpha.com/news/3392554-petiq-readies-stock-offering-shares-down-3-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3392554-petiq-readies-stock-offering-shares-down-3-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392542\" data-ts=\"1537819593\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASNA\" target=\"_blank\">ASNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392542-ascena-retail-group-beats-0_05-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ascena Retail Group beats by $0.05, beats on revenue</a></h4><ul><li>Ascena Retail Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group Inc'>ASNA</a>): Q4 Non-GAAP EPS of $0.07 <span style=\"color:green\">beats by $0.05</span>; GAAP EPS of $0.17.</li><li>Revenue of $1.76B (+6.0% Y/Y) <font color='green'>beats by $140M</font>.</li><li>Shares <font color='green'>+10%</font>.</li><li><a href='https://seekingalpha.com/pr/17279019-ascena-retail-group-inc-reports-fourth-quarter-fiscal-2018-results-comparable-sales-4-percent'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3392542\" data-linked=\"Ascena Retail Group beats by $0.05, beats on revenue\" data-tweet=\"$ASNA - Ascena Retail Group beats by $0.05, beats on revenue https://seekingalpha.com/news/3392542-ascena-retail-group-beats-0_05-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3392542-ascena-retail-group-beats-0_05-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392535\" data-ts=\"1537818270\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BCDA\" target=\"_blank\">BCDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392535-biocardias-cardiamp-cell-therapy-shows-encouraging-action-in-heart-failure-study-shares-up-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioCardia&#39;s CardiAMP cell therapy shows encouraging action in heart failure study; shares up 7%</a></h4><ul><li>Ultra-thinly traded nano cap BioCardia (<a href='https://seekingalpha.com/symbol/BCDA' title='BioCardia, Inc.'>OTCQB:BCDA</a> <font color='green'>+7.2%</font>) is up on almost a 10x surge in volume, albeit on turnover of only 56K shares, following its <a href=\"https://seekingalpha.com/pr/17278898-positive-data-biocardias-investigational-cardiamp-cell-therapy-heart-failure-presented\" target=\"_blank\">announcement</a> of positive data from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02438306?term=biocardia&amp;rank=1\" target=\"_blank\">CardiAMP-HF</a>, evaluating its <a href=\"http://www.biocardia.com/pipeline/cardiamp-cell-therapy-system/id/8\" target=\"_blank\">CardiAMP stem cell therapy</a> in heart failure patients. The results were presented at the Transcatheter Cardiovascular Therapeutics conference in San Diego.</li><li>At month 9, 10 patients in the roll-in cohort experienced clinically meaningful improvements in symptoms, quality of life and exercise capacity (specifics not provided).</li><li>One-year results will be presented at the American Heart Association Scientific Sessions in Chicago in early November.</li><li>A review of published articles on clinical trials together with an FDA report on adverse events showed a lower rate of treatment-emergent major adverse cardiac events &#40;MACE&#41; for the company's <a href=\"http://www.biocardia.com/products/helix-biotherapeutic-delivery-system/id/18\" target=\"_blank\">Helix Biotherapeutics Delivery System</a>&nbsp;compared to other systems. Specifically, the MACE rate for Helix was 0.3% compared to 1.2 - 5.0% for others. In addition, the use of Helix was not associated with any deaths while the mortality rate for other approaches was 0.39 - 0.83%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392535\" data-linked=\"BioCardia&#39;s CardiAMP cell therapy shows encouraging action in heart failure study; shares up 7%\" data-tweet=\"$BCDA - BioCardia&#39;s CardiAMP cell therapy shows encouraging action in heart failure study; shares up 7% https://seekingalpha.com/news/3392535-biocardias-cardiamp-cell-therapy-shows-encouraging-action-in-heart-failure-study-shares-up-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3392535-biocardias-cardiamp-cell-therapy-shows-encouraging-action-in-heart-failure-study-shares-up-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392533\" data-ts=\"1537817095\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSTM\" target=\"_blank\">VSTM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392533-fda-oks-verastems-duvelisib-shares-up-3-trade-halt\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Verastem&#39;s duvelisib; shares up 3% before trade halt</a></h4><ul><li>Verastem (<a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a> <font color='green'>+3.3%</font>) is up on 43% higher volume (before Nasdaq suspended trading) in response to <a href=\"https://www.streetinsider.com/Corporate+News/Verastems+%28VSTM%29+COPIKTRA+%28duvelisib%29+receives+FDA+approval/14636524.html\" target=\"_blank\">FDA accelerated approval </a>for duvelisib, branded as COPIKTRA, for the treatment of adult patients with relapsed/refractory chronic lymphocytic leukemia &#40;CLL&#41; or small lymphocytic lymphoma &#40;SLL&#41; after at least two prior lines of therapy and adult patients with relapsed/refractory follicular lymphoma &#40;FL&#41; after at least two prior lines of therapy.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3344312-fda-accepts-verastems-marketing-application-blood-cancer-med-duvelisib-action-date-october-5\" target=\"_blank\">FDA accepts Verastem's marketing application for blood cancer med duvelisib, action date October 5; shares up 33% premarket</a> (April 9)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392533\" data-linked=\"FDA OKs Verastem&#39;s duvelisib; shares up 3% before trade halt\" data-tweet=\"$VSTM - FDA OKs Verastem&#39;s duvelisib; shares up 3% before trade halt https://seekingalpha.com/news/3392533-fda-oks-verastems-duvelisib-shares-up-3-trade-halt?source=tweet\" data-url=\"https://seekingalpha.com/news/3392533-fda-oks-verastems-duvelisib-shares-up-3-trade-halt\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>44&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392526\" data-ts=\"1537815313\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMNY\" target=\"_blank\">HMNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392526-technology-top-5-gainers-losers-of-2_55-pm-09-24-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 2.55 PM (09/24/2018)</a></h4><ul>     <li><strong>Gainers:</strong> <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/IPDN' title='Professional Diversity Network'>IPDN</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/UXIN' title='Uxin'>UXIN</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/NTWK' title='NetSol Technologies Inc.'>NTWK</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/LEDS' title='SemiLEDs Corporation'>LEDS</a> <font color='green'>+8%</font>.</li>      <li><strong>Losers:</strong> <a href='https://seekingalpha.com/symbol/AWSM' title='Cool Holdings Inc.'>AWSM</a> <font color='red'>-30%</font>. <a href='https://seekingalpha.com/symbol/IDN' title='Intellicheck Mobilisa, Inc.'>IDN</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/QTT' title='Qutoutiao'>QTT</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/NTNX' title='Nutanix'>NTNX</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/JG' title='Aurora Mobile'>JG</a> <font color='red'>-9%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3392526\" data-linked=\"Technology - Top 5 Gainers / Losers as of 2.55 PM (09/24/2018)\" data-tweet=\"$HMNY $HMNY $IPDN - Technology - Top 5 Gainers / Losers as of 2.55 PM (09/24/2018) https://seekingalpha.com/news/3392526-technology-top-5-gainers-losers-of-2_55-pm-09-24-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3392526-technology-top-5-gainers-losers-of-2_55-pm-09-24-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392524\" data-ts=\"1537813891\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNC\" target=\"_blank\">GNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392524-gnc-holdingsplus-8-short-battle-goes-on\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GNC Holdings +8% as short battle goes on</a></h4><ul> <li>GNC Holdings (NYSE:<a href='https://seekingalpha.com/symbol/GNC' title='GNC Holdings, Inc.'>GNC</a>) is <font color='green'>up 7.5%</font> to stand as one of leading gaining gainers in the consumer goods sector on the day.</li> <li>Once again, volume on GNC is elevated the amid the ongoing long vs. short battle.</li> <li>GNC is up 36% over the last month.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3392524\" data-linked=\"GNC Holdings +8% as short battle goes on\" data-tweet=\"$GNC - GNC Holdings +8% as short battle goes on https://seekingalpha.com/news/3392524-gnc-holdingsplus-8-short-battle-goes-on?source=tweet\" data-url=\"https://seekingalpha.com/news/3392524-gnc-holdingsplus-8-short-battle-goes-on\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392521\" data-ts=\"1537812505\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTCH\" target=\"_blank\">MTCH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392521-match-group-responds-to-bumbles-suit-pursuit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Match Group responds to Bumble&#39;s suit pursuit</a></h4><ul><li>        Match Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MTCH' title='Match Group, Inc.'>MTCH</a>) <a href=\"https://techcrunch.com/2018/09/24/match-group-responds-to-bumble-lawsuit-this-has-no-substance/?utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+Techcrunch+%28TechCrunch%29\" target=\"_blank\">responds</a> to rival Bumble&rsquo;s plans to continue its countersuit for impacting its business by obtaining confidential information under the guise of a potential acquisition.</li><li>               Match&rsquo;s statement to TechCrunch: &ldquo;Our statement on this lawsuit is the same today as it was six months ago: we obviously think this has no substance. To our knowledge, Bumble still has not served us. However, we understand their desire to distract from ongoing, actual litigation, regarding their misappropriation of trade secrets and infringing on our intellectual property. Bumble is required to file a response to our original claims next week and we look forward to proving these in court.&rdquo;&nbsp;</li><li>               Bumble says it has served Match Group through the Texas Secretary of State&rsquo;s office, which is where Match HQ is located.&nbsp;</li><li>               Match Group shares are&nbsp;<font color='green'>up 1.1%</font>&nbsp;to $55.97.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392430-bumble-continues-match-countersuit-plans-ipo\" target=\"_blank\">Bumble continues Match countersuit, plans IPO</a> (Sept. 24)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392521\" data-linked=\"Match Group responds to Bumble&#39;s suit pursuit\" data-tweet=\"$MTCH - Match Group responds to Bumble&#39;s suit pursuit https://seekingalpha.com/news/3392521-match-group-responds-to-bumbles-suit-pursuit?source=tweet\" data-url=\"https://seekingalpha.com/news/3392521-match-group-responds-to-bumbles-suit-pursuit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392520\" data-ts=\"1537812469\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SAEX\" target=\"_blank\">SAEX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392520-energy-materials-top-5-gainers-losers-of-2-07-pm-09-24-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials  - Top 5 Gainers / Losers as of 2:07 PM (09/24/2018)</a></h4><ul><li><b>Gainers:&nbsp;</b><a href='https://seekingalpha.com/symbol/SAEX' title='SAExploration Holdings, Inc.'>SAEX</a> <font color='green'>+200%</font>. <a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a> <font color='green'>+90%</font>. <a href='https://seekingalpha.com/symbol/JONE' title='Jones Energy, Inc.'>OTC:JONE</a> <font color='green'>+33.9%</font>. <a href='https://seekingalpha.com/symbol/PED' title='PEDEVCO Corp.'>PED</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/CRC' title='California Resources Corporation'>CRC</a> <font color='green'>+16%</font>.<b> </b></li><b> Losers:</b> <a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/ROSE' title='Rosehill Resources Inc.'>ROSE</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/GPL' title='Great Panther Silver Limited'>GPL</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/CENX' title='Century Aluminum Company'>CENX</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/DRD' title='DRDGOLD Limited'>DRD</a> <font color='red'>-4%</font>.  </ul><div class=\"tiny-share-widget\" data-id=\"3392520\" data-linked=\"Energy/Materials  - Top 5 Gainers / Losers as of 2:07 PM (09/24/2018)\" data-tweet=\"$SAEX $SAEX $GBR - Energy/Materials - Top 5 Gainers / Losers as of 2:07 PM (09/24/2018) https://seekingalpha.com/news/3392520-energy-materials-top-5-gainers-losers-of-2-07-pm-09-24-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3392520-energy-materials-top-5-gainers-losers-of-2-07-pm-09-24-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392519\" data-ts=\"1537812141\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBEV\" target=\"_blank\">NBEV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392519-new-age-beveragesminus-37-after-filing-to-sell-shares-for-cbd-funding\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Age Beverages -37% after filing to sell shares for CBD funding</a></h4><ul> <li>New Age Beverages (NASDAQ:<a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a>) is <font color='green'>down 37%</font> after disclosing an \"at the market\" agreement with Roth Capital to sell new shares as the company looks to fund its CBD-infused beverage play.</li> <li>Despite today's downturn, shares of NBEV are up more than 150% over the last 30 days.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3392519\" data-linked=\"New Age Beverages -37% after filing to sell shares for CBD funding\" data-tweet=\"$NBEV - New Age Beverages -37% after filing to sell shares for CBD funding https://seekingalpha.com/news/3392519-new-age-beveragesminus-37-after-filing-to-sell-shares-for-cbd-funding?source=tweet\" data-url=\"https://seekingalpha.com/news/3392519-new-age-beveragesminus-37-after-filing-to-sell-shares-for-cbd-funding\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392514\" data-ts=\"1537811485\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBEV\" target=\"_blank\">NBEV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392514-new-age-beverages-enters-market-offering-agreement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Age Beverages enters into At the Market Offering Agreement</a></h4><ul>     <li>New Age Beverages (<a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='red'>-36.8%</font>) have <a href=\"https://www.sec.gov/Archives/edgar/data/1579823/000165495418010402/nbev_8k.htm\" target=\"_blank\">entered into an At the Market Offering Agreement</a> with Roth Capital Partners LLC., pursuant to which the Company may offer and sell from time to time up to an aggregate of $50M shares of the Company&rsquo;s common stock.</li>     <li>The Company intends to use the net proceeds from this offering for investing in its portfolio of CBD-infused beverages and for general working capital purposes.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392514\" data-linked=\"New Age Beverages enters into At the Market Offering Agreement\" data-tweet=\"$NBEV - New Age Beverages enters into At the Market Offering Agreement https://seekingalpha.com/news/3392514-new-age-beverages-enters-market-offering-agreement?source=tweet\" data-url=\"https://seekingalpha.com/news/3392514-new-age-beverages-enters-market-offering-agreement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392511\" data-ts=\"1537810928\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VG\" target=\"_blank\">VG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392511-vonageplus-1_8-william-blair-starts-outperform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vonage +1.8% as William Blair starts at Outperform</a></h4><ul>   <li>Vonage Holdings (NYSE:<a href='https://seekingalpha.com/symbol/VG' title='Vonage Holdings Corp.'>VG</a>) is <font color='green'>up 1.8%</font> today after an assumption at Outperform by William Blair.</li>    <li>That rating follows closely on Vonage's deal to <a href=\"https://seekingalpha.com/news/3391695-vonage-buys-contact-center-service-company-350m\" target=\"_blank\">buy NewVoiceMedia for $350M in cash</a>.</li>    <li>Shares have strung together a nice year, moving <font color='green'>up 26.4%</font> over the past six months and <font color='green'>up 70.1%</font> over the past 12.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392511\" data-linked=\"Vonage +1.8% as William Blair starts at Outperform\" data-tweet=\"$VG - Vonage +1.8% as William Blair starts at Outperform https://seekingalpha.com/news/3392511-vonageplus-1_8-william-blair-starts-outperform?source=tweet\" data-url=\"https://seekingalpha.com/news/3392511-vonageplus-1_8-william-blair-starts-outperform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392508\" data-ts=\"1537810170\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABMD\" target=\"_blank\">ABMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392508-abiomed-up-8-on-strong-performance-of-impella-heart-pumps\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Abiomed up 8% on strong performance of Impella heart pumps</a></h4><ul><li>Abiomed (<a href='https://seekingalpha.com/symbol/ABMD' title='ABIOMED, Inc.'>ABMD</a> <font color='green'>+8.1%</font>) is up average volume on the heels of its <a href=\"https://seekingalpha.com/pr/17278158-data-presented-tct-2018-shows-use-impella-best-practices-increases-cardiogenic-shock-survival\" target=\"_blank\">announcement </a>of results from a new analysis of real-world data from its Impella Quality Database that showed a relative increase of 24% in average survival in acute myocardial infarction cardiogenic shock patients since Impella's U.S. approval for cardiogenic shock.</li><li>The company says part of the reason for the increase was a near-doubling in the number of hospital centers achieving more than an 80% survival rate to explant.</li><li>The results were presented at the Transcatheter Cardiovascular Therapeutics conference in San Diego.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392508\" data-linked=\"Abiomed up 8% on strong performance of Impella heart pumps\" data-tweet=\"$ABMD - Abiomed up 8% on strong performance of Impella heart pumps https://seekingalpha.com/news/3392508-abiomed-up-8-on-strong-performance-of-impella-heart-pumps?source=tweet\" data-url=\"https://seekingalpha.com/news/3392508-abiomed-up-8-on-strong-performance-of-impella-heart-pumps\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392506\" data-ts=\"1537810006\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPOT\" target=\"_blank\">SPOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392506-analysts-see-sirius-xm-success-likely-in-pandora-bid\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts see Sirius XM success likely in Pandora bid</a></h4><ul>   <li>Sirius XM (<a href=\"http://seekingalpha.com/symbol/SIRI\" target=\"_blank\">SIRI</a> <font color='red'>-8.3%</font>) is likely to come through successfully with its <a href=\"https://seekingalpha.com/news/3392334-sirius-xm-buying-pandora-3_5b-deal\" target=\"_blank\">bid for Pandora Media</a> (<a href=\"http://seekingalpha.com/symbol/P\" target=\"_blank\">P</a> <font color='green'>+1.3%</font>), analysts say, with few antitrust issues likely to get in the way and little likelihood of a higher bidder.</li>    <li>Mark Mahaney at RBC theorizes Pandora could see interest in a go-shop period from Spotify (NYSE:<a href='https://seekingalpha.com/symbol/SPOT' title='Spotify'>SPOT</a>), Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>), Google (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a>, <a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a>) or Amazon.com (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) -- but thinks it's reasonably unlikely that any of them would step in with a topper of a deal that has a \"reasonable\" valuation. He's sticking with an Outperform rating on Pandora. (h/t Bloomberg)</li>    <li>Evercore ISI agrees there's likely to be no meaningful antitrust issues and is \"somewhat skeptical\" of a higher bid coming in. Analyst Vijay Jayant thinks the combination will be focused on EBITDA and free cash flow more than just subscriber and revenue growth, and expects negative free cash flow at Pandora will help cut fully taxed free cash flow per share by about 7% in 2019, he says. He's rated Sirius XM in-line with a $6 price target vs. current price of $6.40.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392506\" data-linked=\"Analysts see Sirius XM success likely in Pandora bid\" data-tweet=\"$SPOT $SPOT $AAPL - Analysts see Sirius XM success likely in Pandora bid https://seekingalpha.com/news/3392506-analysts-see-sirius-xm-success-likely-in-pandora-bid?source=tweet\" data-url=\"https://seekingalpha.com/news/3392506-analysts-see-sirius-xm-success-likely-in-pandora-bid\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392459\" data-ts=\"1537809535\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABT\" target=\"_blank\">ABT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392459-cardiac-device-makers-in-green-on-positive-data-industry-conference\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cardiac device makers in the green on positive data at industry conference</a></h4><ul><li>Medical device makers operating in the cardiology space are seeing a spike in buying, stoked by the release of positive trial data from several participants at the Transcatheter Therapeutics Conference in San Diego.</li><li>Abbott (<a href='https://seekingalpha.com/symbol/ABT' title='Abbott Laboratories'>ABT</a> <font color='green'>+3.2%</font>) <a href=\"https://seekingalpha.com/pr/17277701-landmark-study-shows-treatment-abbotts-mitraclip-superior-medical-therapy-advanced-heart\" target=\"_blank\">announced </a>successful results from its COAPT study that showed the use of its MitraClip device plus medical therapy in patients with secondary mitral regurgitation (leaky heart valve) was superior to medial therapy alone.</li><li>Selected tickers: (<a href='https://seekingalpha.com/symbol/EW' title='Edwards Lifesciences Corp'>EW</a> <font color='green'>+6.4%</font>)(<a href='https://seekingalpha.com/symbol/MDT' title='Medtronic plc'>MDT</a> <font color='green'>+0.4%</font>)(<a href='https://seekingalpha.com/symbol/BSX' title='Boston Scientific Corporation'>BSX</a> <font color='green'>+1%</font>)(<a href='https://seekingalpha.com/symbol/CYTK' title='Cytokinetics, Incorporated'>CYTK</a> <font color='green'>+8.2%</font>)(<a href='https://seekingalpha.com/symbol/ABMD' title='ABIOMED, Inc.'>ABMD</a> <font color='green'>+8.2%</font>)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392440-medtronics-resolute-onyx-des-beats-biotroniks-orsiro-stent-real-world-study\" target=\"_blank\">Medtronic's Resolute Onyx DES beats Biotronik's Orsiro stent in real-world study</a> (Sept. 24)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392336-fda-oks-boston-scientifics-eluvia-des-shares-1-percent-premarket\" target=\"_blank\">FDA OKs Boston Scientific's Eluvia DES; shares up 1% premarket</a> (Sept. 24)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392459\" data-linked=\"Cardiac device makers in the green on positive data at industry conference\" data-tweet=\"$ABT $ABT $EW - Cardiac device makers in the green on positive data at industry conference https://seekingalpha.com/news/3392459-cardiac-device-makers-in-green-on-positive-data-industry-conference?source=tweet\" data-url=\"https://seekingalpha.com/news/3392459-cardiac-device-makers-in-green-on-positive-data-industry-conference\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392495\" data-ts=\"1537808892\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DAL\" target=\"_blank\">DAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392495-airlines-tumble-oil-surges\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Airlines tumble as oil surges</a></h4><ul><li><a href=\"https://seekingalpha.com/news/3392477-crude-oil-rallies-highs-day-energy-shares-surging\" target=\"_blank\">Brent crude oil today</a> is&nbsp;<font color='green'>up 3%</font>&nbsp;and has topped $81 per barrel for the first time in four years. WTI crude is ahead a similar amount and topping $72.</li><li>The U.S. Global Jets ETF (<a href='https://seekingalpha.com/symbol/JETS' title='U.S. Global Jets ETF'>JETS</a> <font color='red'>-2.5%</font>)</li><li>Delta (<a href='https://seekingalpha.com/symbol/DAL' title='Delta Air Lines, Inc.'>DAL</a> <font color='red'>-3.9%</font>), JetBlue (<a href='https://seekingalpha.com/symbol/JBLU' title='JetBlue Airways Corporation'>JBLU</a> <font color='red'>-2.9%</font>), American Airlines (<a href='https://seekingalpha.com/symbol/AAL' title='American Airlines Group'>AAL</a> <font color='red'>-3.1%</font>), Southwest (<a href='https://seekingalpha.com/symbol/LUV' title='Southwest Airlines Co.'>LUV</a> <font color='red'>-3.1%</font>), United (<a href='https://seekingalpha.com/symbol/UAL' title='United Continental Holdings, Inc'>UAL</a> <font color='red'>-3%</font>), Spirit (<a href='https://seekingalpha.com/symbol/SAVE' title='Spirit Airlines'>SAVE</a> <font color='red'>-3.9%</font>)</li><li>Airlines, in turn, are dragging the Dow Transports&nbsp;<font color='red'>lower by 1.6%</font>&nbsp;vs. just a&nbsp;<font color='red'>0.5% pullback</font>&nbsp;for the S&amp;P 500.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/IYT' title='iShares Transportation Average ETF'>IYT</a>, <a href='https://seekingalpha.com/symbol/XTN' title='SPDR S&P Transportation ETF'>XTN</a>, <a href='https://seekingalpha.com/symbol/FTXR' title='First Trust Nasdaq Transportation ETF'>FTXR</a>, <a href='https://seekingalpha.com/symbol/XKST' title='SPDR Kensho Smart Mobility ETF'>XKST</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3392495\" data-linked=\"Airlines tumble as oil surges\" data-tweet=\"$DAL $JETS $DAL - Airlines tumble as oil surges https://seekingalpha.com/news/3392495-airlines-tumble-oil-surges?source=tweet\" data-url=\"https://seekingalpha.com/news/3392495-airlines-tumble-oil-surges\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392494\" data-ts=\"1537808819\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EIGR\" target=\"_blank\">EIGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392494-fda-on-board-design-of-pivotal-study-for-eigers-pegylated-interferon-alfa-shares-up-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA on board with design of pivotal study for Eiger&#39;s pegylated interferon-alfa; shares up 5%</a></h4><ul><li>Thinly traded micro cap Eiger BioPharmaceuticals (<a href='https://seekingalpha.com/symbol/EIGR' title='Eiger BioPharmaceuticals, Inc.'>EIGR</a> <font color='green'>+5%</font>)&nbsp; in up on average volume of 62K shares on the heels of its <a href=\"https://seekingalpha.com/pr/17278116-eiger-announces-fda-guidance-hdv-phase-3-study-design-primary-endpoint-established-d-livr\" target=\"_blank\">announcement</a> that the FDA agrees with its design for a pivotal Phase 3 study, D-LIVR, that will support accelerated approval for two lonafarnib-based, ritonavir-boosted regimens to treat hepatitis delta virus &#40;HDV&#41; infection.</li><li>The study will include an all-oral arm of lonafarnib (AbbVie's Norvir) boosted with ritonavir and a combination arm of lonafarnib with ritonavir combined with Eiger's pegylated interferon-alfa, both compared to placebo. Another arm with pegylated interferon-alfa alone will be used to demonstrate contribution of effect only.</li><li>The co-primary endpoints will be at least a 2 log(10) decline (100-fold reduction) in HDV RNA and normalization of a biomarker for liver disease called alanine aminotransferase &#40;ALT&#41; at week 48.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3378690-enrollment-underway-eigers-mid-stage-study-pegylated-interferon-lambda-hdv\" target=\"_blank\">Enrollment underway in Eiger's mid-stage study of pegylated interferon lambda in HDV</a> (Aug. 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392494\" data-linked=\"FDA on board with design of pivotal study for Eiger&#39;s pegylated interferon-alfa; shares up 5%\" data-tweet=\"$EIGR - FDA on board with design of pivotal study for Eiger&#39;s pegylated interferon-alfa; shares up 5% https://seekingalpha.com/news/3392494-fda-on-board-design-of-pivotal-study-for-eigers-pegylated-interferon-alfa-shares-up-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3392494-fda-on-board-design-of-pivotal-study-for-eigers-pegylated-interferon-alfa-shares-up-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392493\" data-ts=\"1537808818\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PMTS\" target=\"_blank\">PMTS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392493-financials-top-5-gainers-losers-of-1-05-pm-09-24-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:05 PM (09/24/2018)</a></h4><ul><li><b>Gainers:&nbsp;&nbsp;</b><a href='https://seekingalpha.com/symbol/PMTS' title='CPI Card Group'>PMTS</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/VCTR' title='Victory Capital Holdings, Inc.'>VCTR</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/FPAY' title='FlexShopper, Inc.'>FPAY</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/LTS' title='Ladenburg Thalmann Financial Services Inc.'>LTS</a> <font color='green'>+6%</font>.</li><li><b>Losers: </b><a href='https://seekingalpha.com/symbol/CWH' title='Camping World Holdings'>CWH</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/PPDF' title='PPDAI Group Inc.'>PPDF</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/SUPV' title='Grupo Supervielle'>SUPV</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/WHLR' title='Wheeler Real Estate Investment Trust'>WHLR</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/COR' title='CoreSite Realty Corporation'>COR</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392493\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:05 PM (09/24/2018)\" data-tweet=\"$PMTS $PMTS $VCTR - Financials - Top 5 Gainers / Losers as of 1:05 PM (09/24/2018) https://seekingalpha.com/news/3392493-financials-top-5-gainers-losers-of-1-05-pm-09-24-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3392493-financials-top-5-gainers-losers-of-1-05-pm-09-24-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392487\" data-ts=\"1537807523\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MPC\" target=\"_blank\">MPC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392487-marathon-andeavor-shareholders-ok-merger-creating-largest-u-s-refiner\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marathon, Andeavor shareholders OK merger, creating largest U.S. refiner</a></h4><ul><li>Shareholders of Marathon Petroleum (<a href='https://seekingalpha.com/symbol/MPC' title='Marathon Petroleum Corp.'>MPC</a> <font color='green'>+3.1%</font>) and Andeavor (<a href='https://seekingalpha.com/symbol/ANDV' title='Andeavor'>ANDV</a> <font color='green'>+2.9%</font>) have <a href=\"https://www.chron.com/business/energy/article/Andeavor-Marathon-shareholders-approve-merger-13253493.php\" target=\"_blank\">voted to approve a merger</a> to create the largest U.S. oil refiner, surpassing Valero Energy (<a href='https://seekingalpha.com/symbol/VLO' title='Valero Energy Corporation'>VLO</a> <font color='green'>+3.4%</font>).</li><li>MPC, currently the second largest U.S. refiner, will acquire ANDV, ranked no. 5, in a deal valued at $35.6B including debt.</li><li>Separately, two refineries owned by ANDV are among six with direct access to oil out of the Permian Basin that are <a href=\"https://www.chron.com/business/energy/article/Permian-refineries-in-Texas-New-Mexico-reaping-13253158.php\" target=\"_blank\">making margins above $15/bbl</a> ($9M/day) when processing  West Texas Intermediate, West Texas Sour or a mix of the two, according to a Morningstar  report.</li><li>The refineries also include one each run by VLO, HollyFrontier (<a href='https://seekingalpha.com/symbol/HFC' title='HollyFrontier Corp.'>HFC</a> <font color='green'>+5.1%</font>), Delek US Holdings (<a href='https://seekingalpha.com/symbol/DK' title='Delek US Holdings, Inc.'>DK</a> <font color='green'>+2.6%</font>), and a joint venture by Philips 66 (<a href='https://seekingalpha.com/symbol/PSX' title='Phillips 66'>PSX</a> <font color='green'>+1.8%</font>) and Cenovus Energy (<a href='https://seekingalpha.com/symbol/CVE' title='Cenovus Energy, Inc.'>CVE</a> <font color='green'>+2.9%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3392487\" data-linked=\"Marathon, Andeavor shareholders OK merger, creating largest U.S. refiner\" data-tweet=\"$MPC $MPC $ANDV - Marathon, Andeavor shareholders OK merger, creating largest U.S. refiner https://seekingalpha.com/news/3392487-marathon-andeavor-shareholders-ok-merger-creating-largest-u-s-refiner?source=tweet\" data-url=\"https://seekingalpha.com/news/3392487-marathon-andeavor-shareholders-ok-merger-creating-largest-u-s-refiner\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392485\" data-ts=\"1537807018\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DFBG-OLD\" target=\"_blank\">DFBG-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392485-apparel-stocks-lower-on-trade-war-anxiety\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apparel stocks lower on trade war anxiety</a></h4><ul> <li>Select apparel stocks trade lower after China imposed new tariffs on U.S. products.</li> <li>Decliners include Differential Brands Group (<a href='https://seekingalpha.com/symbol/DFBG-OLD' title='Differential Brands Group Inc.'>DFBG-OLD</a> <font color='red'>-4.2%</font>), G-III Apparel (<a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, LTD.'>GIII</a> <font color='red'>-4%</font>), Crown Crafts (<a href='https://seekingalpha.com/symbol/CRWS' title='Crown Crafts, Inc.'>CRWS</a> <font color='red'>-3.4%</font>), Hanebrands (<a href='https://seekingalpha.com/symbol/HBI' title='Hanesbrands Inc.'>HBI</a> <font color='red'>-2.8%</font>), Ralph Lauren (<a href='https://seekingalpha.com/symbol/RL' title='Ralph Lauren Corporation'>RL</a> <font color='red'>-2%</font>), Fossil (<a href='https://seekingalpha.com/symbol/FOSL' title='Fossil, Inc.'>FOSL</a> <font color='red'>-3.3%</font>), Rocky Brands (<a href='https://seekingalpha.com/symbol/RCKY' title='Rocky Brands, Inc.'>RCKY</a> <font color='red'>-2.3%</font>), Steven Madden (<a href='https://seekingalpha.com/symbol/SHOO' title='Steven Madden, Ltd.'>SHOO</a> <font color='red'>-1.9%</font>), Vera Bradley (<a href='https://seekingalpha.com/symbol/VRA' title='Vera Bradley'>VRA</a> <font color='red'>-1.8%</font>), Tapestry (<a href='https://seekingalpha.com/symbol/TPR' title='Tapestry, Inc.'>TPR</a> <font color='red'>-1.9%</font>) and Oxford Industries (<a href='https://seekingalpha.com/symbol/OXM' title='Oxford Industries Inc.'>OXM</a> <font color='red'>-2.2%</font>).</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3392485\" data-linked=\"Apparel stocks lower on trade war anxiety\" data-tweet=\"$DFBG-OLD $DFBG-OLD $GIII - Apparel stocks lower on trade war anxiety https://seekingalpha.com/news/3392485-apparel-stocks-lower-on-trade-war-anxiety?source=tweet\" data-url=\"https://seekingalpha.com/news/3392485-apparel-stocks-lower-on-trade-war-anxiety\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392484\" data-ts=\"1537806913\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRN\" target=\"_blank\">AMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392484-midday-gainers-losers-09-24-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (09/24/2018)</a></h4><ul>     <li><strong>Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation PLC'>AMRN</a> <font color='green'>+233%</font>. <a href='https://seekingalpha.com/symbol/SAEX' title='SAExploration Holdings, Inc.'>SAEX</a> <font color='green'>+153%</font>. <a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a> <font color='green'>+41%</font>. <a href='https://seekingalpha.com/symbol/JONE' title='Jones Energy, Inc.'>OTC:JONE</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/IPCI' title='IntelliPharmaCeutics International Inc'>IPCI</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/XON' title='Intrexon Corp'>XON</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/CRC' title='California Resources Corporation'>CRC</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/AGTC' title='Applied Genetic Technologies Corporation'>AGTC</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/PEIX' title='Pacific Ethanol, Inc.'>PEIX</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/ACHV' title='Achieve Life Sciences, Inc.'>ACHV</a> <font color='green'>+15%</font>.</li>     <li><strong>Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/ALT' title='Altimmune, Inc.'>ALT</a> <font color='red'>-49%</font>. <a href='https://seekingalpha.com/symbol/ASTC' title='Astrotech Corporation'>ASTC</a> <font color='red'>-39%</font>. <a href='https://seekingalpha.com/symbol/AWSM' title='Cool Holdings Inc.'>AWSM</a> <font color='red'>-33%</font>. <a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='red'>-32%</font>. <a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a> <font color='red'>-26%</font>. <a href='https://seekingalpha.com/symbol/NITE' title='Nightstar Therapeutics plc'>NITE</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/LITB' title='LightInTheBox Holding Co., Ltd.'>LITB</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/JAKK' title='JAKKS Pacific, Inc.'>JAKK</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/JG' title='Aurora Mobile'>JG</a> <font color='red'>-12%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3392484\" data-linked=\"Midday Gainers / Losers (09/24/2018)\" data-tweet=\"$AMRN $AMRN $SAEX - Midday Gainers / Losers (09/24/2018) https://seekingalpha.com/news/3392484-midday-gainers-losers-09-24-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3392484-midday-gainers-losers-09-24-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392480\" data-ts=\"1537806452\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LH\" target=\"_blank\">LH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392480-labcorp-takes-issue-dismissal-of-lawsuit-over-medicare-cuts-for-lab-testing-shares-down-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LabCorp takes issue with dismissal of lawsuit over Medicare cuts for lab testing; shares down 2%</a></h4><ul><li>LabCorp (<a href='https://seekingalpha.com/symbol/LH' title='Laboratory Corporation of America Holdings'>LH</a> <font color='red'>-2%</font>) is down on below-average volume in response to its <a href=\"https://seekingalpha.com/pr/17277989-labcorp-statement-district-court-opinion-acla-lawsuit-hhs\" target=\"_blank\">announcement </a>that a district court has dismissed its lawsuit aimed at stopping the implementation of Medicare reimbursement cuts for laboratory testing.</li><li>The company remains hopeful that it can stop the action. It says the court stated that its arguments raise \"important questions\" about the data gathering by the Centers for Medicare &amp; Medicaid Services &#40;CMS&#41;, adding that it is \"evaluating its options.\"</li><li>Peer Quest Diagnostics (<a href='https://seekingalpha.com/symbol/DGX' title='Quest Diagnostics Incorporated'>DGX</a> <font color='red'>-1%</font>) is down as well.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392480\" data-linked=\"LabCorp takes issue with dismissal of lawsuit over Medicare cuts for lab testing; shares down 2%\" data-tweet=\"$LH $LH $DGX - LabCorp takes issue with dismissal of lawsuit over Medicare cuts for lab testing; shares down 2% https://seekingalpha.com/news/3392480-labcorp-takes-issue-dismissal-of-lawsuit-over-medicare-cuts-for-lab-testing-shares-down-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3392480-labcorp-takes-issue-dismissal-of-lawsuit-over-medicare-cuts-for-lab-testing-shares-down-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:27 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392477\" data-ts=\"1537806053\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XOM\" target=\"_blank\">XOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392477-crude-oil-rallies-to-highs-of-day-energy-shares-surging\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude oil rallies to highs of the day; energy shares surging</a></h4><ul>     <li>Crude oil climbs to highs of the day amid a tightening oil market and OPEC leaders signaling they <a href=\"https://seekingalpha.com/news/3392302-brent-crude-spikes-fresh-four-year-high-near-81-bbl\" target=\"_blank\">would not raise production</a> for now; <a href=\"https://www.cnbc.com/2018/09/24/brent-crude-breaks-80-its-highest-since-2014-as-oil-market-tightens.html\" target=\"_blank\">Brent crude breaches $81/bbl</a> for the first time in four years, <font color='green'>+3%</font> to $81.19/bbl, with WTI crude <font color='green'>+2.4%</font> to $72.48/bbl.</li>     <li>In its latest market outlook, J.P. Morgan says \"a spike to $90/bbl is likely\" in the coming months thanks to U.S. sanctions on Iranian oil exports, which have been falling sharply and could lead to a loss of 1.5M bbl/day from the market.</li>     <li>Commodity traders Trafigura and Mercuria think Brent could rise to $90 by Christmas and <a href=\"https://www.reuters.com/article/us-global-oil/oil-jumps-2-percent-in-tightening-market-traders-tip-more-gains-idUSKCN1M401E\" target=\"_blank\">pass $100 in early 2019</a>, forecasting nearly 2M bbl/day of crude could be taken out of the market.</li>     <li>The current bout of upward buying pressures likely will persist through to the end of the year, says PVM&nbsp;Oil Associates analyst Stephen Brennock, but \"the oil balance in the early part of 2019 makes very bad reading for oil bulls with a sizable supply surplus penciled in by the leading energy  agencies.\"</li><li>Among oil and gas stocks: <a href='https://seekingalpha.com/symbol/XOM' title='Exxon Mobil Corporation'>XOM</a> <font color='green'>+1.6%</font>, <a href='https://seekingalpha.com/symbol/CVX' title='Chevron Corporation'>CVX</a> <font color='green'>+0.7%</font>, <a href='https://seekingalpha.com/symbol/BP' title='BP p.l.c.'>BP</a> <font color='green'>+1.4%</font>, <a href='https://seekingalpha.com/symbol/RDS.A' title='Royal Dutch Shell plc'>RDS.A</a> <font color='green'>+1.2%</font>, <a href='https://seekingalpha.com/symbol/COP' title='ConocoPhillips'>COP</a> <font color='green'>+1.4%</font>, <a href='https://seekingalpha.com/symbol/MRO' title='Marathon Oil Corporation'>MRO</a> <font color='green'>+1.3%</font>, <a href='https://seekingalpha.com/symbol/MPC' title='Marathon Petroleum Corp.'>MPC</a> <font color='green'>+2.7%</font>, <a href='https://seekingalpha.com/symbol/PXD' title='Pioneer Natural Resources Company'>PXD</a> <font color='green'>+1.2%</font>, <a href='https://seekingalpha.com/symbol/DVN' title='Devon Energy Corporation'>DVN</a> <font color='green'>+1.8%</font>, <a href='https://seekingalpha.com/symbol/APA' title='Apache Corporation'>APA</a> <font color='green'>+2.9%</font>, <a href='https://seekingalpha.com/symbol/CLR' title='Continental Resources, Inc.'>CLR</a> <font color='green'>+3.5%</font>, <a href='https://seekingalpha.com/symbol/APC' title='Anadarko Petroleum Corporation'>APC</a> <font color='green'>+1.8%</font>, <a href='https://seekingalpha.com/symbol/CHK' title='Chesapeake Energy Corporation'>CHK</a> <font color='green'>+4.6%</font>, <a href='https://seekingalpha.com/symbol/CRC' title='California Resources Corporation'>CRC</a> <font color='green'>+16%</font>, <a href='https://seekingalpha.com/symbol/RIG' title='Transocean Ltd.'>RIG</a> <font color='green'>+0.9%</font>, <a href='https://seekingalpha.com/symbol/ESV' title='Ensco PLC'>ESV</a> <font color='green'>+3.9%</font>, <a href='https://seekingalpha.com/symbol/NE' title='Noble Corporation plc'>NE</a> <font color='green'>+3.8%</font>, <a href='https://seekingalpha.com/symbol/OAS' title='Oasis Petroleum Inc.'>OAS</a> <font color='green'>+5%</font>, <a href='https://seekingalpha.com/symbol/WLL' title='Whiting Petroleum Corporation'>WLL</a> <font color='green'>+5.2%</font>, <a href='https://seekingalpha.com/symbol/DNR' title='Denbury Resources Inc.'>DNR</a> <font color='green'>+9.3%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/XLE' title='Energy Select Sector SPDR ETF'>XLE</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UWT' title='VelocityShares 3X Long Crude ETN'>UWT</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/VDE' title='Vanguard Energy ETF'>VDE</a>, <a href='https://seekingalpha.com/symbol/XOP' title='SPDR S&P Oil & Gas Exploration & Production ETF'>XOP</a>, <a href='https://seekingalpha.com/symbol/DWT' title='VelocityShares 3x Inverse Crude Oil ETN'>DWT</a>, <a href='https://seekingalpha.com/symbol/ERX' title='Direxion Daily Energy Bull 3x Shares ETF'>ERX</a>, <a href='https://seekingalpha.com/symbol/OIH' title='VanEck Vectors Oil Services ETF'>OIH</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='Invesco DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/ERY' title='Direxion Daily Energy Bear 3x Shares ETF'>ERY</a>, <a href='https://seekingalpha.com/symbol/DIG' title='ProShares Ultra Oil & Gas ETF'>DIG</a>, <a href='https://seekingalpha.com/symbol/BGR' title='BlackRock Energy&Resources Trust'>BGR</a>, <a href='https://seekingalpha.com/symbol/GUSH' title='Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 3x Shares ETF'>GUSH</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/FENY' title='Fidelity MSCI Energy Index ETF'>FENY</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/IYE' title='iShares U.S. Energy ETF'>IYE</a>, <a href='https://seekingalpha.com/symbol/DUG' title='ProShares UltraShort Oil & Gas ETF'>DUG</a>, <a href='https://seekingalpha.com/symbol/DRIP' title='Direxion Daily S&P Oil & Gas Exp. & Prod. Bear 3x Shares ETF'>DRIP</a>, <a href='https://seekingalpha.com/symbol/IEO' title='iShares U.S. Oil & Gas Exploration & Production ETF'>IEO</a>, <a href='https://seekingalpha.com/symbol/FIF' title='First Trust Energy Infrastructure Fund'>FIF</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/NDP' title='Tortoise Energy Independence Fund'>NDP</a>, <a href='https://seekingalpha.com/symbol/PXE' title='Invesco Dynamic Energy Exploration & Production Portfolio ETF'>PXE</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/RYE' title='Invesco S&P Equal Weight Energy ETF'>RYE</a>, <a href='https://seekingalpha.com/symbol/PXJ' title='Invesco Dynamic Oil & Gas Services Portfolio ETF'>PXJ</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/CRAK' title='VanEck Vectors Oil Refiners ETF'>CRAK</a>, <a href='https://seekingalpha.com/symbol/FXN' title='First Trust Energy AlphaDEX ETF'>FXN</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a>, <a href='https://seekingalpha.com/symbol/WTIU' title='ProShares Daily 3x Long Crude ETN'>WTIU</a>, <a href='https://seekingalpha.com/symbol/DDG' title='ProShares Short Oil & Gas ETF'>DDG</a>, <a href='https://seekingalpha.com/symbol/OILK' title='ProShares K-1 Free Crude Oil Strategy ETF'>OILK</a>, <a href='https://seekingalpha.com/symbol/NANR' title='SPDR S&P North American Natural Resources ETF'>NANR</a>, <a href='https://seekingalpha.com/symbol/OILX' title='Etracs S&P GSCI Crude Oil Total Return Index ETN'>OILX</a>, <a href='https://seekingalpha.com/symbol/WTID' title='ProShares Daily 3x Inverse Crude ETN'>WTID</a>, <a href='https://seekingalpha.com/symbol/USOI' title='Credit Suisse Crude Oil Shares Covered Call ETN'>USOI</a>, <a href='https://seekingalpha.com/symbol/USOU' title='United States 3x Oil Fund'>USOU</a>, <a href='https://seekingalpha.com/symbol/USOD' title='United States 3x Short Oil Fund ETF'>USOD</a>, <a href='https://seekingalpha.com/symbol/FTXN' title='First Trust Nasdaq Oil & Gas ETF'>FTXN</a>, <a href='https://seekingalpha.com/symbol/JHME' title='John Hancock Multifactor Energy ETF'>JHME</a>, <a href='https://seekingalpha.com/symbol/ERYY' title='Direxion Daily Energy Bear 1x Shares ETF'>ERYY</a>, <a href='https://seekingalpha.com/symbol/ERGF' title='iShares Edge MSCI Multifactor Energy ETF'>ERGF</a>, <a href='https://seekingalpha.com/symbol/OILD' title='ProShares UltraPro 3x Short Crude Oil ETF'>OILD</a>, <a href='https://seekingalpha.com/symbol/OILU' title='ProShares UltraPro 3x Crude Oil ETF'>OILU</a>, <a href='https://seekingalpha.com/symbol/USAI' title='American Energy Independence ETF'>USAI</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3392477\" data-linked=\"Crude oil rallies to highs of the day; energy shares surging\" data-tweet=\"$XOM $XOM $CVX - Crude oil rallies to highs of the day; energy shares surging https://seekingalpha.com/news/3392477-crude-oil-rallies-to-highs-of-day-energy-shares-surging?source=tweet\" data-url=\"https://seekingalpha.com/news/3392477-crude-oil-rallies-to-highs-of-day-energy-shares-surging\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>65&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392475\" data-ts=\"1537805978\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392475-snap-jumps-on-visual-shopping-deal-amazon\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Snap jumps on visual-shopping deal with Amazon</a></h4><ul>   <li>Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) jumped to its session high and is now <font color='green'>up 1%</font> on word that it's <a href=\"https://www.snap.com/en-US/news/post/introducing-visual-search/\" target=\"_blank\">partnering with Amazon.com</a> (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) to allow shopping directly from Snapchat.</li>    <li>Users will be able to use visual search by pointing the app's camera at an item and quickly locate and buy it from Amazon without leaving the app.</li><li>The search also works by pointing at a product barcode.</li><li>Snap says it's rolling the feature out slowly to all users.</li><li>Shares briefly pegged a <font color='green'>2.2% gain</font> before falling back a bit.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392475\" data-linked=\"Snap jumps on visual-shopping deal with Amazon\" data-tweet=\"$SNAP $SNAP $AMZN - Snap jumps on visual-shopping deal with Amazon https://seekingalpha.com/news/3392475-snap-jumps-on-visual-shopping-deal-amazon?source=tweet\" data-url=\"https://seekingalpha.com/news/3392475-snap-jumps-on-visual-shopping-deal-amazon\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392474\" data-ts=\"1537805895\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIG\" target=\"_blank\">SIG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392474-signet-falls-on-report-of-amazons-interest-in-selling-jewelry-online\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Signet falls on report of Amazon&#39;s interest in selling jewelry online</a></h4><ul> <li>Shares of Signet Jewelers (NYSE:<a href='https://seekingalpha.com/symbol/SIG' title='Signet Jewelers Limited'>SIG</a>) are <font color='red'>down 2.6%</font> after Business Insider <a href=\"https://www.businessinsider.com/amazon-patents-for-keeps-by-amazon-for-jewelry-2018-9?r=UK&amp;IR=T\" target=\"_blank\">reports</a> that Amazon filed a patent covering the online retail sales of jewelry.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3392474\" data-linked=\"Signet falls on report of Amazon&#39;s interest in selling jewelry online\" data-tweet=\"$SIG - Signet falls on report of Amazon&#39;s interest in selling jewelry online https://seekingalpha.com/news/3392474-signet-falls-on-report-of-amazons-interest-in-selling-jewelry-online?source=tweet\" data-url=\"https://seekingalpha.com/news/3392474-signet-falls-on-report-of-amazons-interest-in-selling-jewelry-online\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392471\" data-ts=\"1537805722\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPPI\" target=\"_blank\">SPPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392471-spectrum-pharma-down-4-following-release-of-updated-data-on-poziotinib-in-lung-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spectrum Pharma down 4% following release of updated data on poziotinib in lung cancer</a></h4><ul><li>Spectrum Pharmaceuticals (<a href='https://seekingalpha.com/symbol/SPPI' title='Spectrum Pharmaceuticals, Inc.'>SPPI</a> <font color='red'>-4.1%</font>) slips on average volume following its <a href=\"https://seekingalpha.com/pr/17278738-spectrum-pharmaceuticals-announces-release-updated-poziotinib-data-md-anderson-phase-2-study\" target=\"_blank\">announcement </a>of interim data from a Phase 2 clinical trial evaluating pan-HER inhibitor poziotinib in heavily pretreated patients with EGFR exon 20-mutant non-small cell lung cancer &#40;NSCLC&#41;. The results were presented at the World Conference on Lung Cancer in Toronto.</li><li>The objective response rate so far is 43%, down from 58% announced several weeks ago and 64% in April.</li><li>Median progression-free survival &#40;PFS&#41; to date is 5.5 months.</li><li>Initial responses were observed in 50% (n=6/12) of evaluable patients with HER2 exon 20-mutant NSCLC. Median PFS is currently 5.1 months.</li><li>Management will host a conference call today at 4:30 pm ET to discuss the results.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3388275-spectrum-pharmas-poziotinib-continues-show-positive-action-mid-stage-lung-cancer-study-shares\" target=\"_blank\">Spectrum Pharma's poziotinib continues to show positive action in mid-stage lung cancer study; shares up 7% premarket</a> (Sept. 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392471\" data-linked=\"Spectrum Pharma down 4% following release of updated data on poziotinib in lung cancer\" data-tweet=\"$SPPI - Spectrum Pharma down 4% following release of updated data on poziotinib in lung cancer https://seekingalpha.com/news/3392471-spectrum-pharma-down-4-following-release-of-updated-data-on-poziotinib-in-lung-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3392471-spectrum-pharma-down-4-following-release-of-updated-data-on-poziotinib-in-lung-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392470\" data-ts=\"1537804883\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTFT\" target=\"_blank\">FTFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392470-consumer-top-gainers-losers-of-12-00-pm-09-24-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 PM (09/24/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/FTFT' title='Future Fintech Group Inc'>FTFT</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/SONO' title='Sonos, Inc.'>SONO</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/REV' title='Revlon, Inc.'>REV</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='red'>-26%</font>. KORS <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/REED' title='Reed&#39;s, Inc.'>REED</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/AVP' title='Avon Products, Inc.'>AVP</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/NWL' title='Newell Brands Inc.'>NWL</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392470\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 PM (09/24/2018)\" data-tweet=\"$FTFT $FTFT $SONO - Consumer - Top Gainers / Losers as of 12:00 PM (09/24/2018) https://seekingalpha.com/news/3392470-consumer-top-gainers-losers-of-12-00-pm-09-24-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3392470-consumer-top-gainers-losers-of-12-00-pm-09-24-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392468\" data-ts=\"1537804608\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MD\" target=\"_blank\">MD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392468-leerink-bullish-on-mednax-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Leerink bullish on MEDNAX, shares up 2%</a></h4><ul><li>MEDNAX (<a href='https://seekingalpha.com/symbol/MD' title='Mednax, Inc.'>MD</a> <font color='green'>+1.9%</font>) is up on below-average volume early in the session. Leerink's Ana Gupte (OUTPERFORM/$56) has a rosy outlook for the company citing its improved margins and growing share in neonatal sales. She believes the company could be an acquisition target in the medium term.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392468\" data-linked=\"Leerink bullish on MEDNAX, shares up 2%\" data-tweet=\"$MD - Leerink bullish on MEDNAX, shares up 2% https://seekingalpha.com/news/3392468-leerink-bullish-on-mednax-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3392468-leerink-bullish-on-mednax-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392464\" data-ts=\"1537804424\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRN\" target=\"_blank\">AMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392464-citi-sees-another-5x-upside-in-amarin\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citi sees another 5x upside in Amarin</a></h4><ul><li>Amarin (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation PLC'>AMRN</a>) has&nbsp;<font color='green'>skyrocketed more than 200%</font>&nbsp;to $10.15 today after its fish oil capsule showed big benefits in a trial of more than 8K patients with elevated risk of heart issues.</li><li>Assuming the expanded REDUCE-IT label is granted, Citi sees peak sales of a whopping $2.7B. That assumes only about 2M of the 50B-70B eligible patients are treated. The team there sees upside to $50 per share, with Amarin being a strong acquisition target. Source: <a href=\"https://twitter.com/thenotablecalls\" target=\"_blank\">Notable Calls</a></li><li>Also on the move on the news is Acasti Pharma (<a href='https://seekingalpha.com/symbol/ACST' title='Acasti Pharma, Inc.'>ACST</a> <font color='green'>+26.9%</font>), whose heart pill candidate CaPre is mostly made up of omega-3 fatty acids.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392323-amarin-reports-positive-results-reduce-study-shares-307-percent-premarket\" target=\"_blank\">Amarin reports positive results from REDUCE-IT study; shares up 307% premarket</a> (Sept. 24)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392464\" data-linked=\"Citi sees another 5x upside in Amarin\" data-tweet=\"$AMRN $AMRN $ACST - Citi sees another 5x upside in Amarin https://seekingalpha.com/news/3392464-citi-sees-another-5x-upside-in-amarin?source=tweet\" data-url=\"https://seekingalpha.com/news/3392464-citi-sees-another-5x-upside-in-amarin\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>88&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392463\" data-ts=\"1537804346\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIO\" target=\"_blank\">BIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392463-jefferies-bullish-on-bio-rad-shares-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jefferies bullish on Bio-Rad; shares up 3%</a></h4><ul><li>In a note, Jefferies' Brandon Couillard (BUY/$420) is bullish on Bio-Rad Laboratories (<a href='https://seekingalpha.com/symbol/BIO' title='Bio-Rad Laboratories, Inc.'>BIO</a> <font color='green'>+3.2%</font>) citing its underappreciated droplet digital PCR franchise. He says the \"disruptive\" technology is capable of driving sustained organic growth acceleration through 2021.</li><li>Mr. Couillard also says the company has more cash tied up in working capital than its peers.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392463\" data-linked=\"Jefferies bullish on Bio-Rad; shares up 3%\" data-tweet=\"$BIO - Jefferies bullish on Bio-Rad; shares up 3% https://seekingalpha.com/news/3392463-jefferies-bullish-on-bio-rad-shares-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3392463-jefferies-bullish-on-bio-rad-shares-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392458\" data-ts=\"1537803495\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392458-ming-chi-kuo-iphone-xs-max-4x-sales-of-xs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ming-Chi Kuo: iPhone XS Max has 4x sales of XS</a></h4><ul><li>        Respected analyst Ming-Chi Kuo is <a href=\"https://9to5mac.com/2018/09/24/kuo-iphone-xs-max-more-popular-than-xs/\" target=\"_blank\">out with details</a> about last week&rsquo;s launch of Apple&rsquo;s (<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a> <font color='green'>+0.9%</font>) iPhone XS and XS Max.</li><li>               Kuo thinks the iPhone XS Max is selling 3x to 4x better than the XS with most consumers opting for the 256GB (or middle) models.&nbsp;                  Kuo says there could be a shortage of 512GB models since Samsung is the primary supplier of the NAND flash chips.&nbsp;</li><li>               The analyst raises his estimates for iPhone XS Max shipments 5% to 10% for 2H18, which will help maintain his prior estimate of 75M to 80M iPhone sales despite lower XS sales, and is confident the sales will continue to grow in the holiday quarter.&nbsp;</li><li>               The popularity combo of the Max and 256GB storage size could shoot the average selling price for iPhones to above the expected $750 to $770 range.&nbsp;</li><li>               Apple&rsquo;s Watch Series 4 is selling better than expected and Kuo increases his estimate for the year from 18M to 18.5M to 19.5M.&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392020-new-iphones-apple-watch-go-sale\" target=\"_blank\">New iPhones, Apple Watch go on sale</a> (Sept. 21)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392294-modems-routers-slammed-new-u-s-tariffs-smart-tech-goods-escape\" target=\"_blank\">Modems, routers slammed by new U.S. tariffs but 'smart' tech goods escape</a> (Sept. 24)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392300-risky-business-apple-seeks-streaming-success-without-violence-sex\" target=\"_blank\">Risky business: Apple seeks streaming success without violence, sex</a> (Sept. 24)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392458\" data-linked=\"Ming-Chi Kuo: iPhone XS Max has 4x sales of XS\" data-tweet=\"$AAPL - Ming-Chi Kuo: iPhone XS Max has 4x sales of XS https://seekingalpha.com/news/3392458-ming-chi-kuo-iphone-xs-max-4x-sales-of-xs?source=tweet\" data-url=\"https://seekingalpha.com/news/3392458-ming-chi-kuo-iphone-xs-max-4x-sales-of-xs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392455\" data-ts=\"1537802925\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARNC\" target=\"_blank\">ARNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392455-ny-post-hefty-arconic-price-tag-scare-off-potential-bidders\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NY Post: Hefty Arconic price tag could scare off potential bidders</a></h4><ul><li>A leveraged buyout of Arconic (<a href='https://seekingalpha.com/symbol/ARNC' title='Arconic Inc'>ARNC</a> <font color='red'>-3%</font>) has hit a snag, as potential bidders including Apollo Global  Management (NYSE:<a href='https://seekingalpha.com/symbol/APO' title='Apollo Global Management, LLC'>APO</a>), <a href='https://seekingalpha.com/symbol/KKR' title='KKR'>KKR</a> and a group including Blackstone (NYSE:<a href='https://seekingalpha.com/symbol/BX' title='The Blackstone Group L.P.'>BX</a>) and  Carlyle Group (NASDAQ:<a href='https://seekingalpha.com/symbol/CG' title='The Carlyle Group'>CG</a>), have <a href=\"https://nypost.com/2018/09/21/hefty-arconic-price-tag-could-scare-off-potential-bidders/\" target=\"_blank\">grown concerned about price</a>, <em>NY Post </em>reports.</li><li>ARNC sells parts to an aerospace sector  that is at a cyclical high point, pushing up the potential price tag  toward a possible $20B leveraged buyout, according to the report.</li><li>With the possible purchase price rising as orders from Boeing and  other suppliers pick up, a buyer would need the capital structure  in place to protect itself in roughly five years, when the cycle may  reverse and demand for airplane parts may fall, a concern that could limit the amount of leverage a buyer may be prepared to place on the business.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392455\" data-linked=\"NY Post: Hefty Arconic price tag could scare off potential bidders\" data-tweet=\"$ARNC $ARNC $APO - NY Post: Hefty Arconic price tag could scare off potential bidders https://seekingalpha.com/news/3392455-ny-post-hefty-arconic-price-tag-scare-off-potential-bidders?source=tweet\" data-url=\"https://seekingalpha.com/news/3392455-ny-post-hefty-arconic-price-tag-scare-off-potential-bidders\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392453\" data-ts=\"1537802548\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACAD\" target=\"_blank\">ACAD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392453-baker-brothers-stake-in-acadia-pharma-up-to-almost-23\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baker Brothers stake in Acadia Pharma up to almost 23%</a></h4><ul><li>Institutional investor Baker Brothers has <a href=\"https://www.sec.gov/Archives/edgar/data/1070494/000114420418050460/tv503330_sc13da12.htm\" target=\"_blank\">increased its stake</a> in ACADIA Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ACAD' title='ACADIA Pharmaceuticals Inc.'>ACAD</a> <font color='green'>+0.5%</font>) to 22.8% via the purchase of an additional 1.2M shares on September 20.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392453\" data-linked=\"Baker Brothers stake in Acadia Pharma up to almost 23%\" data-tweet=\"$ACAD - Baker Brothers stake in Acadia Pharma up to almost 23% https://seekingalpha.com/news/3392453-baker-brothers-stake-in-acadia-pharma-up-to-almost-23?source=tweet\" data-url=\"https://seekingalpha.com/news/3392453-baker-brothers-stake-in-acadia-pharma-up-to-almost-23\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392452\" data-ts=\"1537802505\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMAL\" target=\"_blank\">AMAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392452-amalgamated-bank-rises-1_1-after-q2-beats-consensus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amalgamated Bank rises 1.1% after Q2 beats consensus</a></h4><ul><li>Amalgamated Bank (NASDAQ:<a href='https://seekingalpha.com/symbol/AMAL' title='Amalgamated Bank'>AMAL</a>)<font color='green'> rises 1.1%</font>&nbsp;after reporting Q2 EPS beat consensus <a href=\"https://seekingalpha.com/news/3392317-amalgamated-bank-beats-0_06-misses-revenue\" target=\"_blank\">by 6 cents</a> in its first quarterly<a href=\"https://seekingalpha.com/pr/17277859-amalgamated-bank-reports-second-quarter-2018-financial-results\" target=\"_blank\"> earnings report</a> since its initial public offering last month.</li><li>Earlier shares rose as much as 2.6%.</li><li>Q2 core earnings rose to $11.8M, or 40 cents per share, compared with $1.0M, or 4 cents in the year ago quarter, partly reflecting its May 2018 acquisition of New Resource Bank.</li><li>Q2 loan growth of $306.2M, or 22% on an annualized basis, from Dec. 31, 2017.</li><li>Net interest margin rose to 3.56% from 3.43% in Q1 and 3.12% in Q2 2017.</li><li>Net interest income increased to $36.7M from $32.8M in Q1 and $29.8M in the year-ago period.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3382162-amalgamated-bank-closes-ipo-7_7m-shares-15_50\" target=\"_blank\">Amalgamated Bank closes IPO of 7.7M shares at $15.50 each</a> (Aug. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392452\" data-linked=\"Amalgamated Bank rises 1.1% after Q2 beats consensus\" data-tweet=\"$AMAL - Amalgamated Bank rises 1.1% after Q2 beats consensus https://seekingalpha.com/news/3392452-amalgamated-bank-rises-1_1-after-q2-beats-consensus?source=tweet\" data-url=\"https://seekingalpha.com/news/3392452-amalgamated-bank-rises-1_1-after-q2-beats-consensus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392448\" data-ts=\"1537802242\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LGND\" target=\"_blank\">LGND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392448-ligand-authorizes-200m-share-repurchase-plan-shares-ahead-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ligand authorizes $200M share repurchase plan; shares ahead 2%</a></h4><ul><li>Ligand Pharmaceuticals (<a href='https://seekingalpha.com/symbol/LGND' title='Ligand Pharmaceuticals Incorporated'>LGND</a> <font color='green'>+2.3%</font>) is up on below-average volume in response to its <a href=\"https://www.sec.gov/Archives/edgar/data/886163/000088616318000137/lgnd-form8xksharerepurchas.htm\" target=\"_blank\">announcement </a>that the board has authorized a three-year $200M shares buyback program.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392448\" data-linked=\"Ligand authorizes $200M share repurchase plan; shares ahead 2%\" data-tweet=\"$LGND - Ligand authorizes $200M share repurchase plan; shares ahead 2% https://seekingalpha.com/news/3392448-ligand-authorizes-200m-share-repurchase-plan-shares-ahead-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3392448-ligand-authorizes-200m-share-repurchase-plan-shares-ahead-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392444\" data-ts=\"1537801590\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSFT\" target=\"_blank\">MSFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392444-microsoft-announces-new-products-partners-sap-and-adobe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microsoft announces new products, partners with SAP and Adobe</a></h4><ul><li>Microsoft (<a href='https://seekingalpha.com/symbol/MSFT' title='Microsoft Corporation'>MSFT</a> <font color=\"red\">-0.3%</font>), Adobe (<a href='https://seekingalpha.com/symbol/ADBE' title='Adobe Systems Incorporated'>ADBE</a> <font color=\"green\">+0.3%</font>), and SAP (<a href='https://seekingalpha.com/symbol/SAP' title='SAP AG'>SAP</a> <font color=\"green\">+0.5%</font>) <a href=\"https://www.bloomberg.com/news/articles/2018-09-24/microsoft-rolls-out-additions-to-office-security-and-cloud-offerings\" target=\"_blank\">announce</a> the partnered Open Data Initiative to create common data standards and put the customer \u201cback in control of their own data.\u201d</li><li>The Initiative will eliminate data silos by combining all of a single customer\u2019s data into one real-time and renewable package for the company to retain.</li><li>Microsoft also introduced new offerings and provided product updates during its Ignite conference.</li><li>Slack rival Teams has 329K organizations as customers including 87 of the Fortune 100.</li><li>Microsoft Windows and Office apps will get a search box that checks both Bing and internal documents and data. Office apps users will also be able to share documents with LinkedIn direct connections.</li><li>Microsoft says it will spend $40M to put its AI products to work helping refugees, disaster response, and children in conjunction with aid organizations like World Bank.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392444\" data-linked=\"Microsoft announces new products, partners with SAP and Adobe\" data-tweet=\"$MSFT $MSFT $ADBE - Microsoft announces new products, partners with SAP and Adobe https://seekingalpha.com/news/3392444-microsoft-announces-new-products-partners-sap-and-adobe?source=tweet\" data-url=\"https://seekingalpha.com/news/3392444-microsoft-announces-new-products-partners-sap-and-adobe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392443\" data-ts=\"1537801503\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392443-ge-sinks-to-lowest-since-july-2009-amid-turbine-problems\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE sinks to lowest since July 2009 amid turbine problems</a></h4><ul>     <li>General Electric (<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a> <font color='red'>-4.4%</font>) <a href=\"https://www.cnbc.com/2018/09/24/ge-shares-fall-to-new-9-year-low.html\" target=\"_blank\">slumps to a new nine-year low</a>, dropping to its lowest level since July 2009.</li><li>Shares fell ~5.5% late <a href=\"https://seekingalpha.com/news/3391847-reuters-ge-says-four-u-s-power-turbines-shut-due-blade-problem\" target=\"_blank\">last week</a> amid reports that at least four of its power turbines in the U.S. were shut down due to turbine blade oxidation.</li>     <li>The stock is <font color='red'>-32%</font>&nbsp;YTD after sinking 45% last year but still has a way to go before it hits its financial crisis low, when it closed at $6.66 on March 5, 2009.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392443\" data-linked=\"GE sinks to lowest since July 2009 amid turbine problems\" data-tweet=\"$GE - GE sinks to lowest since July 2009 amid turbine problems https://seekingalpha.com/news/3392443-ge-sinks-to-lowest-since-july-2009-amid-turbine-problems?source=tweet\" data-url=\"https://seekingalpha.com/news/3392443-ge-sinks-to-lowest-since-july-2009-amid-turbine-problems\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>94&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392442\" data-ts=\"1537801266\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRN\" target=\"_blank\">AMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392442-healthcare-top-5-gainers-losers-of-11-00-09-24-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 AM (09/24/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation PLC'>AMRN</a> <font color='green'>+243%</font>. <a href='https://seekingalpha.com/symbol/XON' title='Intrexon Corp'>XON</a> <font color='green'>+29%</font>. <a href='https://seekingalpha.com/symbol/ACHV' title='Achieve Life Sciences, Inc.'>ACHV</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/AZRX' title='AzurRX Biopharma'>AZRX</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/CNAT' title='Conatus Pharmaceuticals'>CNAT</a> <font color='green'>+15%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ALT' title='Altimmune, Inc.'>ALT</a> <font color='red'>-42%</font>. <a href='https://seekingalpha.com/symbol/NITE' title='Nightstar Therapeutics plc'>NITE</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/OPK' title='OPKO Health, Inc.'>OPK</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/APEN' title='Apollo Endosurgery'>APEN</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/CTXR' title='Citius Pharmaceuticals Inc.'>CTXR</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392442\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 AM (09/24/2018)\" data-tweet=\"$AMRN $AMRN $XON - Healthcare - Top 5 Gainers / Losers as of 11:00 AM (09/24/2018) https://seekingalpha.com/news/3392442-healthcare-top-5-gainers-losers-of-11-00-09-24-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3392442-healthcare-top-5-gainers-losers-of-11-00-09-24-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392441\" data-ts=\"1537800887\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QURE\" target=\"_blank\">QURE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392441-uniqure-advancing-gene-therapy-for-hemophilia-b-shares-up-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UniQure advancing gene therapy for hemophilia B; shares up 6%</a></h4><ul><li>UniQure (<a href='https://seekingalpha.com/symbol/QURE' title='uniQure N.V.'>QURE</a> <font color='green'>+5.9%</font>) <a href=\"https://seekingalpha.com/pr/17277958-uniqure-provides-update-dose-confirmation-study-amtminus-061-patients-hemophilia-b\" target=\"_blank\">announces </a>that the third patient has been dosed in its Phase 2b clinical trial evaluating gene therapy AMT-061 in patients with severe and moderately severe hemophilia B. The aim of the open-label study is to confirm the dose of AMT-061 prior to treatment in the Phase 3 <a href=\"https://clinicaltrials.gov/ct2/show/NCT03569891?term=uniqure&amp;rank=2\" target=\"_blank\">HOPE-B</a> trial.</li><li>Topline data and dose confirmation should be released by year-end.</li><li>Enrollment is underway in HOPE-B. After a six-month lead-in, participants will receive a single intravenous administration of AMT-061. Dosing should commence in Q1 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392441\" data-linked=\"UniQure advancing gene therapy for hemophilia B; shares up 6%\" data-tweet=\"$QURE - UniQure advancing gene therapy for hemophilia B; shares up 6% https://seekingalpha.com/news/3392441-uniqure-advancing-gene-therapy-for-hemophilia-b-shares-up-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3392441-uniqure-advancing-gene-therapy-for-hemophilia-b-shares-up-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392438\" data-ts=\"1537800122\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392438-deputy-ag-rosenstein-reportedly-resigning-updated-not\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deputy AG Rosenstein reportedly resigning. Updated: Or not</a></h4><ul><li>U.S. averages are giving up a few points on headlines saying Deputy AG Rod Rosenstein is set to resign his post. <a href=\"https://www.axios.com/rod-rosenstein-resign-justice-department-trump-cf761f4c-fca3-4794-92d4-a56c9e32ff43.html\" target=\"_blank\">According to Axios</a>, Rosenstein wants to get his resignation in before he can be fired.</li><li>The S&amp;P 500 is currently<font color='red'> lower by 0.5%</font>.</li><li><strong>Update at 12:20 ET: </strong>Multiple outlets are reporting that Rosenstein has neither resigned nor been fired. Instead he's gone to the White House for a previously scheduled meeting. The S&amp;P remains&nbsp;<font color='red'>down 0.5%</font>.</li><li><strong>Update at 12:55 ET:</strong> The White House<a href=\"https://www.marketwatch.com/story/trump-rosenstein-will-meet-thursday-white-house-says-2018-09-24\" target=\"_blank\"> says the president and Rosenstein</a> will meet on Thursday. Back to our normal programming ...</li></ul><div class=\"tiny-share-widget\" data-id=\"3392438\" data-linked=\"Deputy AG Rosenstein reportedly resigning. Updated: Or not\" data-tweet=\"Deputy AG Rosenstein reportedly resigning. Updated: Or not https://seekingalpha.com/news/3392438-deputy-ag-rosenstein-reportedly-resigning-updated-not?source=tweet\" data-url=\"https://seekingalpha.com/news/3392438-deputy-ag-rosenstein-reportedly-resigning-updated-not\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>117&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392432\" data-ts=\"1537799487\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGO\" target=\"_blank\">EGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392432-animal-spirits-in-gold-miners-after-barricks-purchase-of-randgold\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Animal spirits in gold miners after Barrick&#39;s purchase of Randgold</a></h4><ul><li>Barrick Gold overnight agreed to merge with Randgold Resources in an $18.3B deal. Both Barrick and Randgold are&nbsp;<font color='green'>higher by about 7%</font>.</li><li>The VanEck Vectors Gold Miners ETF (<a href='https://seekingalpha.com/symbol/GDX' title='VanEck Vectors Gold Miners ETF'>GDX</a> <font color='green'>+1.1%</font>)</li><li>Individual players: Eldorado Gold (<a href='https://seekingalpha.com/symbol/EGO' title='Eldorado Gold Corporation'>EGO</a> <font color='green'>+2.6%</font>), Goldcorp (<a href='https://seekingalpha.com/symbol/GG' title='Goldcorp Inc.'>GG</a> <font color='green'>+1.6%</font>), Kinross (<a href='https://seekingalpha.com/symbol/KGC' title='Kinross Gold Corporation'>KGC</a> <font color='green'>+1.9%</font>), AngloGold (<a href='https://seekingalpha.com/symbol/AU' title='AngloGold Ashanti Limited'>AU</a> <font color='green'>+1.7%</font>), Gold Fields (<a href='https://seekingalpha.com/symbol/GFI' title='Gold Fields Limited'>GFI</a> <font color='green'>+4.5%</font>), Iamgold (<a href='https://seekingalpha.com/symbol/IAG' title='IAMGOLD Corporation'>IAG</a> <font color='green'>+4.6%</font>), Yamana Gold (<a href='https://seekingalpha.com/symbol/AUY' title='Yamana Gold Inc.'>AUY</a> <font color='green'>+3.4%</font>), Eldorado Gold (<a href='https://seekingalpha.com/symbol/EGO' title='Eldorado Gold Corporation'>EGO</a> <font color='green'>+3.3%</font>), Royal Gold (<a href='https://seekingalpha.com/symbol/RGLD' title='Royal Gold, Inc.'>RGLD</a> <font color='green'>+2.3%</font>).</li><li>ETFs: <a href='https://seekingalpha.com/symbol/GDX' title='VanEck Vectors Gold Miners ETF'>GDX</a>, <a href='https://seekingalpha.com/symbol/NUGT' title='Direxion Daily Gold Miners Index Bull 3x Shares ETF'>NUGT</a>, <a href='https://seekingalpha.com/symbol/GDXJ' title='VanEck Vectors Junior Gold Miners ETF'>GDXJ</a>, <a href='https://seekingalpha.com/symbol/JNUG' title='Direxion Daily Junior Gold Miners Index Bull 3x Shares ETF'>JNUG</a>, <a href='https://seekingalpha.com/symbol/GGN' title='GAMCO Global Gold, Natural Resources & Income Trust'>GGN</a>, <a href='https://seekingalpha.com/symbol/DUST' title='Direxion Daily Gold Miners Index Bear 3x Shares ETF'>DUST</a>, <a href='https://seekingalpha.com/symbol/JDST' title='Direxion Daily Junior Gold Miners Index Bear 3x Shares ETF'>JDST</a>, <a href='https://seekingalpha.com/symbol/GOEX' title='Global X Gold Explorers ETF'>GOEX</a>, <a href='https://seekingalpha.com/symbol/SGDM' title='Sprott Gold Miners ETF'>SGDM</a>, <a href='https://seekingalpha.com/symbol/ASA' title='ASA Gold&Precious Metals'>ASA</a>, <a href='https://seekingalpha.com/symbol/RING' title='iShares MSCI Global Gold Miners ETF'>RING</a>, <a href='https://seekingalpha.com/symbol/SGDJ' title='Sprott Junior Gold Miners ETF'>SGDJ</a>, <a href='https://seekingalpha.com/symbol/TGLDX' title='Tocqueville Gold Fund No Load'>TGLDX</a>, <a href='https://seekingalpha.com/symbol/PSAU' title='Invesco Global Gold and Precious Metals Portfolio ETF'>PSAU</a>, <a href='https://seekingalpha.com/symbol/GOAU' title='U.S. Global GO GOLD and Precious Metal Miners ETF'>GOAU</a>, <a href='https://seekingalpha.com/symbol/GDXX' title='ProShares Ultra Gold Miners ETF'>GDXX</a>, <a href='https://seekingalpha.com/symbol/GDXS' title='ProShares UltraShort Gold Miners ETF'>GDXS</a>, <a href='https://seekingalpha.com/symbol/MELT' title='Direxion Daily Gold Miners Index Bear 1x Shares ETF'>MELT</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3392296-barrick-gold-buy-randgold-resources-stock-deal\" target=\"_blank\">Barrick Gold to buy Randgold Resources in all-stock deal</a> (Sept. 24)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392432\" data-linked=\"Animal spirits in gold miners after Barrick&#39;s purchase of Randgold\" data-tweet=\"$EGO $GDX $EGO - Animal spirits in gold miners after Barrick&#39;s purchase of Randgold https://seekingalpha.com/news/3392432-animal-spirits-in-gold-miners-after-barricks-purchase-of-randgold?source=tweet\" data-url=\"https://seekingalpha.com/news/3392432-animal-spirits-in-gold-miners-after-barricks-purchase-of-randgold\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392430\" data-ts=\"1537799354\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTCH\" target=\"_blank\">MTCH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392430-bumble-continues-match-countersuit-plans-ipo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bumble continues Match countersuit, plans IPO</a></h4><ul><li>        Dating site Bumble will <a href=\"https://www.cnbc.com/2018/09/24/bumble-serves-countersuit-to-match-is-pursing-ipo.html\" target=\"_blank\">press ahead</a> with its $400M countersuit against Match Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MTCH' title='Match Group, Inc.'>MTCH</a>) after talks failed to result in a deal.</li><li>               Match sued Bumble in March for patent and trademark violations and alleged misuse of trade secrets due to Bumble CEO Whitney Wolfe Herd previously co-founding Tinder.&nbsp;</li><li>               Bumble&rsquo;s countersuit alleges that Match interfered with Bumble&rsquo;s business by asking it to provide confidential information under the guise of pursuing a purchase. &nbsp;&nbsp;</li><li>               As that battle rages on, Bumble preps itself for another fight: a potential IPO.&nbsp;</li><li>               Wolfe Herd says Bumble&rsquo;s growth is at an annual run rate of $200M for the year. The company currently makes money from user subscriptions but will work on bringing in advertising next year.&nbsp;</li><li>               Match shares are&nbsp;<font color='green'>up 1.1%</font>&nbsp;to $55.99.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3340449-match-group-sues-bumble-patent-infringement-bumble-responds\" target=\"_blank\">Match Group sues Bumble for patent infringement, Bumble responds</a> (March 20)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3342577-bumble-sues-match-group-fraud-trade-secret-theft\" target=\"_blank\">Bumble sues Match Group for fraud and trade secret theft</a> (March 29)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3342648-match-group-responds-bumble-lawsuit\" target=\"_blank\">Match Group responds to Bumble lawsuit</a> (March 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392430\" data-linked=\"Bumble continues Match countersuit, plans IPO\" data-tweet=\"$MTCH - Bumble continues Match countersuit, plans IPO https://seekingalpha.com/news/3392430-bumble-continues-match-countersuit-plans-ipo?source=tweet\" data-url=\"https://seekingalpha.com/news/3392430-bumble-continues-match-countersuit-plans-ipo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392427\" data-ts=\"1537799049\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JNJ\" target=\"_blank\">JNJ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392427-j-and-js-esketamine-nasal-spray-flunks-late-stage-study-in-treatment-resistant-depression\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J&amp;J&#39;s esketamine nasal spray flunks late-stage study in treatment-resistant depression</a></h4><ul><li>A Phase 3 clinical trial evaluating two dose strengths (56 mg and 84 mg) of Johnson &amp; Johnson (<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a> <font color='red'>-0.9%</font>) unit Janssen Pharmaceutical's esketamine nasal spray in patients with treatment-resistant depression <a href=\"https://seekingalpha.com/pr/17277626-janssen-announces-results-esketamine-nasal-spray-phase-3-study-patients-treatment-resistant\" target=\"_blank\">failed to demonstrate</a> a statistically valid treatment effect compared to placebo. The data were presented at the Houston Mood Disorders Conference in Texas.</li><li>The study missed the primary endpoint of a statistically significant change in depression severity rating scale score from baseline to week 4 versus placebo for the 84 mg dose cohort. The lower dose could not be formally assessed based on the prespecified analysis plan but the results numerically favored the 56 mg group.</li><li>The company submitted its U.S. marketing application to the FDA several weeks ago.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3387469-johnson-and-johnson-files-u-s-marketing-application-esketamine-nasal-spray-depression\" target=\"_blank\">Johnson &amp; Johnson files U.S. marketing application for esketamine nasal spray for depression</a> (Sept. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392427\" data-linked=\"J&amp;J&#39;s esketamine nasal spray flunks late-stage study in treatment-resistant depression\" data-tweet=\"$JNJ - J&amp;J&#39;s esketamine nasal spray flunks late-stage study in treatment-resistant depression https://seekingalpha.com/news/3392427-j-and-js-esketamine-nasal-spray-flunks-late-stage-study-in-treatment-resistant-depression?source=tweet\" data-url=\"https://seekingalpha.com/news/3392427-j-and-js-esketamine-nasal-spray-flunks-late-stage-study-in-treatment-resistant-depression\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392425\" data-ts=\"1537798756\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CC\" target=\"_blank\">CC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392425-stanley-cuts-estimates-for-chemours-tronox-and-venator-on-tio2-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stanley cuts estimates for Chemours, Tronox and Venator on TiO2 outlook</a></h4><ul>     <li>Chemours (<a href='https://seekingalpha.com/symbol/CC' title='The Chemours Company'>CC</a> <font color='red'>-3.9%</font>), Tronox&nbsp; (<a href='https://seekingalpha.com/symbol/TROX' title='Tronox Inc.'>TROX</a> <font color='red'>-2.7%</font>) and Venator Materials (<a href='https://seekingalpha.com/symbol/VNTR' title='Venator Materials'>VNTR</a> <font color='red'>-6.4%</font>) are all sharply lower after Morgan Stanley cut its estimates and stock price targets, citing expectations that titanium dioxide prices will decline in H2 2018 and into next year.</li>     <li>Capacity utilization has not proven as tight as expected due to inventory destocking and higher than expected Chinese exports, Stanley analyst Vincent Andrews says.</li>     <li>Andrews expects index prices to normalize 5%-10% above marginal cost in 2020 but sees a low probability of a \"bust\" cycle similar to 2011-12.</li>     <li>The firm cuts CC's price target to $47 from $48, TROX to $16 from $21, and VNTR to $10 from $17.50; all three remain rated Equal Weight.</li>     <li>Source:&nbsp;Bloomberg First Word</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392425\" data-linked=\"Stanley cuts estimates for Chemours, Tronox and Venator on TiO2 outlook\" data-tweet=\"$CC $CC $TROX - Stanley cuts estimates for Chemours, Tronox and Venator on TiO2 outlook https://seekingalpha.com/news/3392425-stanley-cuts-estimates-for-chemours-tronox-and-venator-on-tio2-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3392425-stanley-cuts-estimates-for-chemours-tronox-and-venator-on-tio2-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392424\" data-ts=\"1537798668\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DMPI\" target=\"_blank\">DMPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392424-delmar-pharmaceuticals-reports-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DelMar Pharmaceuticals reports Q4 results</a></h4><ul><li>DelMar Pharmaceuticals (<a href='https://seekingalpha.com/symbol/DMPI' title='DelMar Pharmaceuticals, Inc.'>DMPI</a> <font color='green'>+2.7%</font>) <a href=\"https://seekingalpha.com/pr/17277845-delmar-pharmaceuticals-announces-fiscal-year-2018-annual-financial-results\" target=\"_blank\">reports</a> net loss declined 38% to $11.14M.&nbsp;Working Capital down 17.6% to $5.41M.</li><li>The company appointed&nbsp;Saiid Zarrabian&nbsp;as full-time President and Chief Executive Officer.</li><li>The company expects to have cash available to fund planned operations into the middle of calendar 2019, based on overall clinical and corporate development progress achieved to date.</li><li>40 patients enrolled in Phase 2, open-label, second-line, Avastin-na&iuml;ve, MGMT-unmethylated, recurrent glioblastoma multiforme (<a href='https://seekingalpha.com/symbol/GBM' title='GENERAL MTR CV DBS B'>GBM</a>) study being conducted at the MD Anderson Cancer Center (MDACC).</li><li>9 patients have been enrolled in Phase 2, open-label, first-line&nbsp;temozolomide-na&iuml;ve, MGMT-unmethylated GBM study at Sun Yat-sen University Cancer Center.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392424\" data-linked=\"DelMar Pharmaceuticals reports Q4 results\" data-tweet=\"$DMPI $DMPI $GBM - DelMar Pharmaceuticals reports Q4 results https://seekingalpha.com/news/3392424-delmar-pharmaceuticals-reports-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3392424-delmar-pharmaceuticals-reports-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392422\" data-ts=\"1537798279\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOXL\" target=\"_blank\">BOXL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392422-boxlight-acquires-eos-education\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boxlight acquires EOS Education</a></h4><ul>     <li>Boxlight Corporation (<a href='https://seekingalpha.com/symbol/BOXL' title='Boxlight'>BOXL</a> <font color='green'>+3.3%</font>) says that it has completed the acquisition of EOSEDU, LLC for a consideration of 0.1M shares of Boxlight common shares.</li>     <li>EOS Education is a consulting and professional development company for the K-12 education market.</li>     <li>The company expects that its professional services division, post acquisition, will produce ~10% of its total revenues, with gross profit margins greater than 50%.</li><li><a href=\"https://seekingalpha.com/pr/17278103-boxlight-announces-acquisition-eos-education\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3392422\" data-linked=\"Boxlight acquires EOS Education\" data-tweet=\"$BOXL - Boxlight acquires EOS Education https://seekingalpha.com/news/3392422-boxlight-acquires-eos-education?source=tweet\" data-url=\"https://seekingalpha.com/news/3392422-boxlight-acquires-eos-education\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392420\" data-ts=\"1537798236\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392420-hawkish-draghi-remarks-send-euro-higher-stocks-lower\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hawkish Draghi remarks send euro higher, stocks lower</a></h4><ul><li>Inflation readouts may be fairly stable, but they're masking a \"relatively vigorous pickup in underlying inflation,\" says ECB chief Mario Draghi.</li><li><a href=\"https://www.ecb.europa.eu/press/key/date/2018/html/ecb.sp180919.en.html\" target=\"_blank\">Full speech here</a></li><li>The euro (<a href='https://seekingalpha.com/symbol/FXE' title='Invesco CurrencyShares Euro Trust ETF'>FXE</a> <font color='green'>+0.4%</font>) has jumped about 50 pips vs. the dollar on the comments, and European shares (NYSEARCA:<a href='https://seekingalpha.com/symbol/FEZ' title='SPDR EURO STOXX 50 ETF'>FEZ</a>) have turned modestly lower, the Stoxx 600 now&nbsp;<font color='red'>down 0.55%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/FXE' title='Invesco CurrencyShares Euro Trust ETF'>FXE</a>, <a href='https://seekingalpha.com/symbol/VGK' title='Vanguard FTSE Europe ETF'>VGK</a>, <a href='https://seekingalpha.com/symbol/EUO' title='ProShares UltraShort Euro ETF'>EUO</a>, <a href='https://seekingalpha.com/symbol/HEDJ' title='WisdomTree Europe Hedged Equity ETF'>HEDJ</a>, <a href='https://seekingalpha.com/symbol/FEZ' title='SPDR EURO STOXX 50 ETF'>FEZ</a>, <a href='https://seekingalpha.com/symbol/EZU' title='iShares MSCI Eurozone ETF'>EZU</a>, <a href='https://seekingalpha.com/symbol/IEV' title='iShares Europe ETF'>IEV</a>, <a href='https://seekingalpha.com/symbol/ERO' title='iPath EUR/USD Exchange Rate ETN'>ERO</a>, <a href='https://seekingalpha.com/symbol/EPV' title='ProShares UltraShort FTSE Europe ETF'>EPV</a>, <a href='https://seekingalpha.com/symbol/IEUR' title='iShares Core MSCI Europe ETF'>IEUR</a>, <a href='https://seekingalpha.com/symbol/EURL' title='Direxion Daily FTSE Europe Bull 3x Shares ETF'>EURL</a>, <a href='https://seekingalpha.com/symbol/DRR' title='Market Vectors Double Short Euro ETN'>DRR</a>, <a href='https://seekingalpha.com/symbol/FEU' title='SPDR STOXX Europe 50 ETF'>FEU</a>, <a href='https://seekingalpha.com/symbol/ULE' title='ProShares Ultra Euro ETF'>ULE</a>, <a href='https://seekingalpha.com/symbol/DBEU' title='Deutsche X-trackers MSCI Europe Hedged Equity ETF'>DBEU</a>, <a href='https://seekingalpha.com/symbol/EUFX' title='ProShares Short Euro ETF'>EUFX</a>, <a href='https://seekingalpha.com/symbol/HEZU' title='iShares Currency Hedged MSCI EMU ETF'>HEZU</a>, <a href='https://seekingalpha.com/symbol/EEA' title='European Equity Fund'>EEA</a>, <a href='https://seekingalpha.com/symbol/URR' title='Market Vectors Double Long Euro ETN'>URR</a>, <a href='https://seekingalpha.com/symbol/FEEU' title='Barclays ETN+ FI Enhanced Europe 50 ETN'>FEEU</a>, <a href='https://seekingalpha.com/symbol/FEP' title='First Trust Europe AlphaDEX ETF'>FEP</a>, <a href='https://seekingalpha.com/symbol/UPV' title='ProShares Ultra FTSE Europe ETF'>UPV</a>, <a href='https://seekingalpha.com/symbol/ADRU' title='Invesco BLDRS Europe 100 ADR Index ETF'>ADRU</a>, <a href='https://seekingalpha.com/symbol/FEUZ' title='First Trust Eurozone AlphaDex ETF'>FEUZ</a>, <a href='https://seekingalpha.com/symbol/DBEZ' title='Deutsche X-trackers MSCI EMU Hedged Equity ETF'>DBEZ</a>, <a href='https://seekingalpha.com/symbol/FIEU' title='Credit Suisse FI Enhanced Europe 50 ETN'>FIEU</a>, <a href='https://seekingalpha.com/symbol/DEZU' title='iShares Adaptive Currency Hedged MSCI Eurozone ETF'>DEZU</a>, <a href='https://seekingalpha.com/symbol/GSEU' title='Goldman Sachs ActiveBeta Europe Equity ETF'>GSEU</a>, <a href='https://seekingalpha.com/symbol/PTEU' title='Pacer Trendpilo European Index ETF'>PTEU</a>, <a href='https://seekingalpha.com/symbol/FIEE' title='UBS AG FI Enhanced Europe 50 ETN'>FIEE</a>, <a href='https://seekingalpha.com/symbol/HFXE' title='IQ 50 Percent Hedged FTSE Europe ETF'>HFXE</a>, <a href='https://seekingalpha.com/symbol/BBEU' title='JPMorgan BetaBuilders Europe ETF'>BBEU</a>, <a href='https://seekingalpha.com/symbol/DEUR' title='VelocityShares Daily 4X Long USD vs. EUR ETN'>DEUR</a>, <a href='https://seekingalpha.com/symbol/EDOM' title='WisdomTree Europe Domestic Economy ETF'>EDOM</a>, <a href='https://seekingalpha.com/symbol/FLEE' title='Franklin FTSE Europe ETF'>FLEE</a>, <a href='https://seekingalpha.com/symbol/RFEU' title='First Trust RiverFront Dynamic Europe ETF'>RFEU</a>, <a href='https://seekingalpha.com/symbol/UEUR' title='VelocityShares Daily 4X Long EUR vs. USD ETN'>UEUR</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3392420\" data-linked=\"Hawkish Draghi remarks send euro higher, stocks lower\" data-tweet=\"$FXE $FEZ $VGK - Hawkish Draghi remarks send euro higher, stocks lower https://seekingalpha.com/news/3392420-hawkish-draghi-remarks-send-euro-higher-stocks-lower?source=tweet\" data-url=\"https://seekingalpha.com/news/3392420-hawkish-draghi-remarks-send-euro-higher-stocks-lower\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392417\" data-ts=\"1537797957\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BILI\" target=\"_blank\">BILI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392417-bilibiliminus-8-on-analyst-downgrade-lockup-expiration\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bilibili -8% on analyst downgrade, lockup expiration</a></h4><ul><li>        Morgan Stanley<a href=\"https://www.streetinsider.com/Analyst+PT+Change/Morgan+Stanley+Downgrades+Bilibili+%28BILI%29+to+Equalweight/14634173.html\" target=\"_blank\"> downgrades</a> Bilibili (NASDAQ:<a href='https://seekingalpha.com/symbol/BILI' title='Bilibili Inc.'>BILI</a>) from Overweight to Equal Weight and lowers the target from $13.50 to $11.</li><li>               Today marks the expiration of BILI&rsquo;s post-IPO lockup period. &nbsp;&nbsp;</li><li>               BILI is down&nbsp;<font color='red'>8.1%</font>&nbsp;to $11.43.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3392417\" data-linked=\"Bilibili -8% on analyst downgrade, lockup expiration\" data-tweet=\"$BILI - Bilibili -8% on analyst downgrade, lockup expiration https://seekingalpha.com/news/3392417-bilibiliminus-8-on-analyst-downgrade-lockup-expiration?source=tweet\" data-url=\"https://seekingalpha.com/news/3392417-bilibiliminus-8-on-analyst-downgrade-lockup-expiration\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392416\" data-ts=\"1537797888\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEUM\" target=\"_blank\">TEUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392416-pareteumplus-5-on-38m-contract-in-asia\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pareteum +5% on $38M contract in Asia</a></h4><ul>   <li>Pareteum (NYSEMKT:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) is <font color='green'>up 5%</font> after reporting a <a href=\"https://seekingalpha.com/pr/17278268-pareteum-awarded-38-million-contract-asia\" target=\"_blank\">$38M contract</a> with an Internet of Things and MVNO provider in Asia.</li>    <li>The enterprise customer selected Pareteum's Managed Service Platform to power IoT services, filling part of a fully integrated solution using multi-country branded services, digital applications, data services and traditional mobile service.</li>    <li>The customer plans to expand throughout southern Asia and add Wi-Fi, blockchain, M2M and Smart City to its offerings, Pareteum says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392416\" data-linked=\"Pareteum +5% on $38M contract in Asia\" data-tweet=\"$TEUM - Pareteum +5% on $38M contract in Asia https://seekingalpha.com/news/3392416-pareteumplus-5-on-38m-contract-in-asia?source=tweet\" data-url=\"https://seekingalpha.com/news/3392416-pareteumplus-5-on-38m-contract-in-asia\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392415\" data-ts=\"1537797803\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGTC\" target=\"_blank\">AGTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392415-applied-genetic-tech-up-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Applied Genetic Tech up 10%</a></h4><ul><li>Thinly traded nano cap Applied Genetic Technologies (<a href='https://seekingalpha.com/symbol/AGTC' title='Applied Genetic Technologies Corporation'>AGTC</a> <font color='green'>+10.2%</font>) is up on almost a 4x surge in volume, albeit on turnover of only 315K shares, in apparent response to gene therapy peer Nightstar Therapeutics' announcement of positive preliminary data from a study of its gene therapy for X-linked retinitis pigmentosa &#40;XLRP&#41;.</li><li>AGTC is also developing a <a href=\"https://agtc.com/programs/x-linked-retinitis-pigmentosa/\" target=\"_blank\">gene therapy</a> for XLRP.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392410-nighstars-gene-therapy-rare-inherited-retinal-disorder-shows-encouraging-action-phase-1-2\" target=\"_blank\">Nighstar's gene therapy for rare inherited retinal disorder shows encouraging action in Phase 1/2 study</a> (Sept. 24)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392415\" data-linked=\"Applied Genetic Tech up 10%\" data-tweet=\"$AGTC - Applied Genetic Tech up 10% https://seekingalpha.com/news/3392415-applied-genetic-tech-up-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3392415-applied-genetic-tech-up-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392411\" data-ts=\"1537797376\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392411-needham-lowers-micron-target-to-nearly-80-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Needham lowers its Micron target to nearly 80% upside</a></h4><ul><li>        Needham lowers its Micron (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>) target from $100 to $80, a 79% upside to Friday&rsquo;s close.</li><li>                  Firm says that after Micron posted a stellar Q4, the company guided gross margins to decline Q/Q due to the China tariffs and some inventory adjustments.    </li><li>               Needham thinks it will take Micron three to four quarters to resolve the issue, which is disappointing but largely out of Micron&rsquo;s hands.&nbsp;</li><li>               The firm sees a healthy demand/supply balance for DRAM with bit growth of about 20% and demand driver growth of at least 30%.&nbsp;</li><li>                  For NAND, cost reductions will take hold and demand will be greater than supply. &nbsp;   </li><li>               Sources: StreetAccount/<a href=\"https://www.streetinsider.com/Analyst+Comments/Micron+Technology+%28MU%29+PT+Lowered+to+%2480+at+Needham+%26+Company/14634808.html\" target=\"_blank\">StreetInsider</a>.&nbsp;</li><li>               Micron shares are<font color='green'>&nbsp;</font><font color='green'>up 1%</font>&nbsp;to $45.17.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3391966-micron-drops-q4-beats-nand-asps-downside-q1-guidance\" target=\"_blank\">Micron drops after Q4 beats, NAND ASPs down, downside Q1 guidance</a> (Sept. 20)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392085-wsj-intel-responsible-microns-rough-guidance\" target=\"_blank\">WSJ: Intel responsible for Micron's rough guidance?</a> (Sept. 21)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392210-micron-ceo-discusses-tariff-impacts-mitigation\" target=\"_blank\">Micron CEO discusses tariff impacts, mitigation</a> (Sept. 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392411\" data-linked=\"Needham lowers its Micron target to nearly 80% upside\" data-tweet=\"$MU - Needham lowers its Micron target to nearly 80% upside https://seekingalpha.com/news/3392411-needham-lowers-micron-target-to-nearly-80-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3392411-needham-lowers-micron-target-to-nearly-80-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>63&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392410\" data-ts=\"1537797343\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NITE\" target=\"_blank\">NITE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392410-nighstars-gene-therapy-for-rare-inherited-retinal-disorder-shows-encouraging-action-in-phase\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nighstar&#39;s gene therapy for rare inherited retinal disorder shows encouraging action in Phase 1/2 study</a></h4><ul><li>Preliminary data from a Phase 1/2 clinical trial, XIRIUS, evaluating Nightstar Therapeutics' (<a href='https://seekingalpha.com/symbol/NITE' title='Nightstar Therapeutics plc'>NITE</a> <font color='red'>-5.9%</font>) gene therapy NSR-RPGR in patients with X-linked retinitis pigmentosa &#40;XLRP&#41; showed a positive effect. The data were presented at the EURETINA Congress in Vienna.</li><li>On one-month follow-up, all three patients in cohort 3, one of three patients in cohort 4 and one of three patients in cohort 5 experienced an improvement in a visual field test called <a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583893/\" target=\"_blank\">microperimetry</a>.</li><li>Enrollment of 18 adults was completed last month. One-year follow-up data should be available in H2 2019.</li><li>Enrollment in an expansion study should commence next quarter will preliminary results expected in mid-2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392410\" data-linked=\"Nighstar&#39;s gene therapy for rare inherited retinal disorder shows encouraging action in Phase 1/2 study\" data-tweet=\"$NITE - Nighstar&#39;s gene therapy for rare inherited retinal disorder shows encouraging action in Phase 1/2 study https://seekingalpha.com/news/3392410-nighstars-gene-therapy-for-rare-inherited-retinal-disorder-shows-encouraging-action-in-phase?source=tweet\" data-url=\"https://seekingalpha.com/news/3392410-nighstars-gene-therapy-for-rare-inherited-retinal-disorder-shows-encouraging-action-in-phase\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392408\" data-ts=\"1537796967\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AWSM\" target=\"_blank\">AWSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392408-cool-holdingsminus-24-after-short-selling-firm-attacks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cool Holdings -24% after short-selling firm attacks</a></h4><ul> <li>Cool Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/AWSM' title='Cool Holdings Inc.'>AWSM</a>) is <font color='red'>down 25%</font> in early trading as once again TheStreetSweeper issues a negative report.</li> <li>The <a href=\"http://www.thestreetsweeper.org/\" target=\"_blank\">short-selling firm</a> points to issues with Cool Holdings' statements, store traffic and \"flawed\" business model.</li> <li>If Cool Holdings issues a response to the allegations it will be added to this post.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392170-streetsweeper-warns-cool-holdings\" target=\"_blank\">The StreetSweeper warns on Cool Holdings</a> (Sept. 21)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3392408\" data-linked=\"Cool Holdings -24% after short-selling firm attacks\" data-tweet=\"$AWSM - Cool Holdings -24% after short-selling firm attacks https://seekingalpha.com/news/3392408-cool-holdingsminus-24-after-short-selling-firm-attacks?source=tweet\" data-url=\"https://seekingalpha.com/news/3392408-cool-holdingsminus-24-after-short-selling-firm-attacks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392406\" data-ts=\"1537796788\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CY\" target=\"_blank\">CY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392406-cypress-semiminus-5-after-morgan-stanley-lowers-target-margin-forecast\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cypress Semi -5% after Morgan Stanley lowers target, margin forecast</a></h4><ul><li>        Morgan Stanley maintains an Underweight rating on Cypress Semiconductor (NASDAQ:<a href='https://seekingalpha.com/symbol/CY' title='Cypress Semiconductor Corporation'>CY</a>) and lowers its target from $15 to $13.</li><li>               The firm thinks the NOR memory market is nearing a peak, posing growth risks to margins and EPS forecasts as the market softens into 2019.&nbsp;</li><li>               Morgan Stanley lowers its Cypress Semi FY19 margin forecasts for NOR and NAND, which pushes the EPS forecast further below the consensus.&nbsp;</li><li>               Source: StreetAccount.&nbsp;</li><li>               Cypress Semi shares are&nbsp;<font color='red'>down 5.1%</font>&nbsp;to $15.16. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3392406\" data-linked=\"Cypress Semi -5% after Morgan Stanley lowers target, margin forecast\" data-tweet=\"$CY - Cypress Semi -5% after Morgan Stanley lowers target, margin forecast https://seekingalpha.com/news/3392406-cypress-semiminus-5-after-morgan-stanley-lowers-target-margin-forecast?source=tweet\" data-url=\"https://seekingalpha.com/news/3392406-cypress-semiminus-5-after-morgan-stanley-lowers-target-margin-forecast\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392401\" data-ts=\"1537796326\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HSIC\" target=\"_blank\">HSIC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392401-cautious-analyst-note-on-henry-schein-shares-down-1-early\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cautious analyst note on Henry Schein; shares down more than 1% early</a></h4><ul><li><a href=\"https://twitter.com/thenotablecalls\" target=\"_blank\">via Notable Calls</a></li><li>Our work on Henry Schein (<a href='https://seekingalpha.com/symbol/HSIC' title='Henry Schein, Inc.'>HSIC</a> <font color='red'>-1.4%</font>) through early September suggests U.S. dental trends have moderated&nbsp;sequentially across both consumables and equipment, says the team at Cleveland Research.</li><li>Related names: Dentsply Sirona (<a href='https://seekingalpha.com/symbol/XRAY' title='DENTSPLY SIRONA, Inc'>XRAY</a> <font color='red'>-0.9%</font>), Patterson Companies (<a href='https://seekingalpha.com/symbol/PDCO' title='Patterson Companies Inc.'>PDCO</a> <font color='red'>-0.3%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392401\" data-linked=\"Cautious analyst note on Henry Schein; shares down more than 1% early\" data-tweet=\"$HSIC $HSIC $XRAY - Cautious analyst note on Henry Schein; shares down more than 1% early https://seekingalpha.com/news/3392401-cautious-analyst-note-on-henry-schein-shares-down-1-early?source=tweet\" data-url=\"https://seekingalpha.com/news/3392401-cautious-analyst-note-on-henry-schein-shares-down-1-early\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392395\" data-ts=\"1537795779\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHLDQ\" target=\"_blank\">SHLDQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392395-searsplus-10-after-lampert-delivers-restructuring-proposal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sears +10% after Lampert delivers restructuring proposal</a></h4><ul> <li>Sears Holdings (SHLD)&nbsp;jumps in premarket trading after Eddie Lampert delivers a proposal to the board to restructure the company.</li> <li>The proposal includes asset sales and real estate transactions.</li> <li>SHDL <font color='green'>+10.4%</font> premarket to $1.38.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3392395\" data-linked=\"Sears +10% after Lampert delivers restructuring proposal\" data-tweet=\"$SHLDQ - Sears +10% after Lampert delivers restructuring proposal https://seekingalpha.com/news/3392395-searsplus-10-after-lampert-delivers-restructuring-proposal?source=tweet\" data-url=\"https://seekingalpha.com/news/3392395-searsplus-10-after-lampert-delivers-restructuring-proposal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>45&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392394\" data-ts=\"1537795635\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KVHI\" target=\"_blank\">KVHI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392394-kvh-industriesplus-1_6-chardan-lifts-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KVH Industries +1.6% as Chardan lifts to Buy</a></h4><ul>   <li>KVH Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/KVHI' title='KVH Industries, Inc.'>KVHI</a>) is <font color='green'>up 1.6%</font> premarket after an upgrade to Buy at Chardan Capital.</li>    <li>The firm set its price target at $20, implying 63% upside from Friday's close on Nasdaq.</li>    <li>Shares are <font color='red'>down 1.6%</font> in the past quarter, but have <font color='green'>risen 20%</font> over the past six months.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3392394\" data-linked=\"KVH Industries +1.6% as Chardan lifts to Buy\" data-tweet=\"$KVHI - KVH Industries +1.6% as Chardan lifts to Buy https://seekingalpha.com/news/3392394-kvh-industriesplus-1_6-chardan-lifts-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3392394-kvh-industriesplus-1_6-chardan-lifts-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392393\" data-ts=\"1537795582\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RHT\" target=\"_blank\">RHT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392393-red-hat-ceo-explains-q2-revenue-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Red Hat CEO explains Q2 revenue miss</a></h4><ul><li>        Red Hat (NYSE:<a href='https://seekingalpha.com/symbol/RHT' title='Red Hat, Inc.'>RHT</a>) President and CEO Jim Whitehurst <a href=\"https://www.cnbc.com/2018/09/21/red-hat-ceo-we-expect-this-is-the-bottom-in-enterprise-growth.html\" target=\"_blank\">spoke to CNBC&rsquo;s Jim Cramer</a> late last week about the company&rsquo;s Q2 revenue miss.</li><li>               Whitehurst notes that Red Hat started getting customers into three-year agreements about two and a half years ago. The terms give the company more time to sell additional products but also mean the deals don&rsquo;t go up in value every year. The Linux business should recover as those deals come closer to the renewal dates.&nbsp;</li><li>               Whitehurst: &ldquo;We did say we expect this is the bottom and it should re-accelerate from here. We have good visibility and our total backlog grew 20 percent this quarter, so we have a pretty good sense that it&rsquo;ll accelerate from here. Next year, with a lot more renewals from those, you should see more growth.&rdquo;&nbsp;</li><li>               Red Hat shares are&nbsp;<font color='red'>down 0.6%</font>&nbsp;premarket to $133.86.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3391598-red-hat-minus-4-percent-mixed-q2-report-downside-q3-guide\" target=\"_blank\">Red Hat -4% on mixed Q2 report with downside Q3 guide</a> (Sept. 19)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3391785-bmo-oppenheimer-cut-red-hat-targets-earnings\" target=\"_blank\">BMO, Oppenheimer cut Red Hat targets after earnings</a> (Sept. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392393\" data-linked=\"Red Hat CEO explains Q2 revenue miss\" data-tweet=\"$RHT - Red Hat CEO explains Q2 revenue miss https://seekingalpha.com/news/3392393-red-hat-ceo-explains-q2-revenue-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3392393-red-hat-ceo-explains-q2-revenue-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392390\" data-ts=\"1537795500\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMMP\" target=\"_blank\">IMMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392390-immutep-teams-up-merck-kgaa-and-pfizer-in-cancer-combo-therapy-shares-up-7-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immutep teams up with Merck KGaA and Pfizer in cancer combo therapy; shares up 7% premarket</a></h4><ul><li>Thinly traded nano cap Immutep Limited (NASDAQ:<a href='https://seekingalpha.com/symbol/IMMP' title='Immutep Limited ADR'>IMMP</a>) is up&nbsp;<font color='green'>7%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/17278159-immutep-enters-clinical-trial-collaboration-supply-agreement-merck-kgaa-darmstadt-germany\" target=\"_blank\">announced partnership</a> with Merck KGaA (<a href='https://seekingalpha.com/symbol/MKGAF' title='Merck KGaA'>OTCPK:MKGAF</a>)(<a href='https://seekingalpha.com/symbol/MKGAY' title='Merck KGaA ADR'>OTCPK:MKGAY</a>) and Pfizer (NYSE:<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a>) to evaluate the combination of Immuntep's fusion protein eftilagimod alpha and Pfizer's <a href=\"https://www.bavencio.com/en_US/for-us-healthcare-professionals.html\" target=\"_blank\">BAVENCIO </a>(avelumab) in patients with solid tumors.</li><li>A Phase 1 trial will be conducted aimed at evaluating the safety, tolerability and recommended dose of eftilagimod + avelumab in patients with advanced solid malignancies.</li><li>The Institute of Clinical Cancer Research, Krankenhaus Nordwest GmbH in&nbsp;Frankfurt, Germany will sponsor the trial. It will be conducted under the existing protocol of the ongoing INSIGHT clinical study by lead investigator Prof.&nbsp;Dr. Salah-Eddin Al-Batran.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392390\" data-linked=\"Immutep teams up with Merck KGaA and Pfizer in cancer combo therapy; shares up 7% premarket\" data-tweet=\"$IMMP $IMMP $MKGAF - Immutep teams up with Merck KGaA and Pfizer in cancer combo therapy; shares up 7% premarket https://seekingalpha.com/news/3392390-immutep-teams-up-merck-kgaa-and-pfizer-in-cancer-combo-therapy-shares-up-7-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3392390-immutep-teams-up-merck-kgaa-and-pfizer-in-cancer-combo-therapy-shares-up-7-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392387\" data-ts=\"1537795285\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392387-avon-products-tracks-higher-again\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Avon Products tracks higher again</a></h4><ul> <li>Avon Products is <font color='green'>up another 3.7%</font> in premarket action following up on some upward momentum after last week's investor day event hosted by the company.</li> <li>Earlier today, D.A. Davidson upgraded Avon to Buy from Neutral, saying it was impressed by the sense urgency of new CEO Jan Zijderveld and team to improve results.</li> <li>Avon rallied 1.7% on Friday following the investor day good cheer.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3392387\" data-linked=\"Avon Products tracks higher again\" data-tweet=\"Avon Products tracks higher again https://seekingalpha.com/news/3392387-avon-products-tracks-higher-again?source=tweet\" data-url=\"https://seekingalpha.com/news/3392387-avon-products-tracks-higher-again\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392386\" data-ts=\"1537795217\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRN\" target=\"_blank\">AMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392386-premarket-gainers-of-9-05-09-24-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am (09/24/2018)</a></h4><ul><li><a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation PLC'>AMRN</a> <font color='green'>+280%</font>&nbsp;on positive <a href=\"https://seekingalpha.com/news/3392323-amarin-reports-positive-results-reduce-study-shares-307-percent-premarket\" target=\"_blank\">results</a> from REDUCE-IT study.</li><li><a href='https://seekingalpha.com/symbol/AZRX' title='AzurRX Biopharma'>AZRX</a> <font color='green'>+28%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/pr/17278032-azurrx-biopharma-announces-positive-outcome-ms1819-sd-showing-statistically-significant\" target=\"_blank\">achieving</a> in pre-planned analyses, both its primary and secondary endpoints with a statistically significant improvement in the coefficient of fat absorption of 21.8%, in its recent Phase IIa trial of MS1819-SD.</li><li><a href='https://seekingalpha.com/symbol/AGTC' title='Applied Genetic Technologies Corporation'>AGTC</a> <font color='green'>+18%</font>.</li><li><a href='https://seekingalpha.com/symbol/XBIO' title='Xenetic Biosciences, Inc.'>XBIO</a> <font color='green'>+16%</font>.</li><li><a href='https://seekingalpha.com/symbol/SENS' title='Senseonics Holdings'>SENS</a> <font color='green'>+9%</font>.</li><li><a href='https://seekingalpha.com/symbol/P' title='Pandora Media'>P</a> <font color='green'>+7%</font>&nbsp;on being <a href=\"https://seekingalpha.com/news/3392334-sirius-xm-buying-pandora-3_5b-deal\" target=\"_blank\">acquired </a>by Sirius XM.</li><li><a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a> <font color='green'>+7%</font>&nbsp;on $38M <a href=\"https://seekingalpha.com/pr/17278268-pareteum-awarded-38-million-contract-asia\" target=\"_blank\">contract</a> in Asia.</li><li><a href='https://seekingalpha.com/symbol/ALXN' title='Alexion Pharmaceuticals, Inc.'>ALXN</a> <font color='green'>+7%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3392339-alexions-soliris-shows-treatment-effect-late-stage-rare-cns-disorder-shares-5-percent\" target=\"_blank\">treatment</a> effect in late-stage rare CNS disorder.</li><li><a href='https://seekingalpha.com/symbol/NEPT' title='Neptune Wellness Solutions Inc.'>NEPT</a> <font color='green'>+6%</font>.</li><li><a href='https://seekingalpha.com/symbol/GOLD' title='Barrick Gold Corporation'>GOLD</a> <font color='green'>+7%</font>&nbsp;on being <a href=\"https://seekingalpha.com/news/3392296-barrick-gold-buy-randgold-resources-stock-deal\" target=\"_blank\">acquired</a> by Barrick Gold.</li><li><a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group Inc'>ASNA</a> <font color='green'>+5%</font>.</li><li><a href='https://seekingalpha.com/symbol/PDLI' title='PDL BioPharma, Inc.'>PDLI</a> <font color='green'>+6%</font>&nbsp;on new $100M stock repurchase <a href=\"https://seekingalpha.com/pr/17278360-pdl-biopharma-announces-new-100-million-stock-repurchase-program\" target=\"_blank\">program</a>.</li><li><a href='https://seekingalpha.com/symbol/SYMC' title='Symantec Corporation'>SYMC</a> <font color='green'>+5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3392364-symantec-plus-3-percent-competed-audit-committee-investigation\" target=\"_blank\">competed</a> Audit Committee investigation</li></ul><div class=\"tiny-share-widget\" data-id=\"3392386\" data-linked=\"Premarket Gainers as of 9:05 am (09/24/2018)\" data-tweet=\"$AMRN $AMRN $AZRX - Premarket Gainers as of 9:05 am (09/24/2018) https://seekingalpha.com/news/3392386-premarket-gainers-of-9-05-09-24-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3392386-premarket-gainers-of-9-05-09-24-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392383\" data-ts=\"1537794703\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZRX\" target=\"_blank\">AZRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392383-azurrx-bios-ms1819-sd-successful-in-mid-stage-epi-study-shares-ahead-26-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AzurRx Bio&#39;s MS1819-SD successful in mid-stage EPI study; shares ahead 26% premarket</a></h4><ul><li>Thinly traded nano cap AzurRx BioPharma (NASDAQ:<a href='https://seekingalpha.com/symbol/AZRX' title='AzurRX Biopharma'>AZRX</a>) is up&nbsp;<font color='green'>26%&nbsp;</font>premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/17278032-azurrx-biopharma-announces-positive-outcome-ms1819-sd-showing-statistically-significant\" target=\"_blank\">announcement </a>of positive results from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03481803?term=NCT03481803&amp;rank=1\" target=\"_blank\">Phase 2a clinical trial</a> evaluating MS1819-SD, a recombinant lipase, for the treatment of exocrine pancreatic insufficiency &#40;EPI&#41; caused by chronic pancreatitis.</li><li>The study met the primary safety endpoint and the secondary efficacy endpoint, demonstrating a statistically significant 21.8% improvement in the coefficient of fat absorption from baseline.</li><li>Complete results will be presented at an upcoming medical conference.</li></ul><div class=\"tiny-share-widget\" data-id=\"3392383\" data-linked=\"AzurRx Bio&#39;s MS1819-SD successful in mid-stage EPI study; shares ahead 26% premarket\" data-tweet=\"$AZRX - AzurRx Bio&#39;s MS1819-SD successful in mid-stage EPI study; shares ahead 26% premarket https://seekingalpha.com/news/3392383-azurrx-bios-ms1819-sd-successful-in-mid-stage-epi-study-shares-ahead-26-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3392383-azurrx-bios-ms1819-sd-successful-in-mid-stage-epi-study-shares-ahead-26-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392375\" data-ts=\"1537793940\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMAT\" target=\"_blank\">AMAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392375-citi-removes-applied-materials-from-focus-list\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citi removes Applied Materials from its Focus List</a></h4><ul><li>        Citi <a href=\"https://www.streetinsider.com/Analyst+Comments/Applied+Materials+%28AMAT%29+Removed+from+Citi+Focus+List/14633952.html\" target=\"_blank\">removes</a> Applied Materials (NASDAQ:<a href='https://seekingalpha.com/symbol/AMAT' title='Applied Materials, Inc.'>AMAT</a>) from its Focus List but remains at a Buy rating.</li><li>               Analyst Atif Malik cites a leak of near-term catalysts.&nbsp;</li><li>               Applied Materials has suffered from the recent semi industry pressures and stumbled after its Q3 report in mid-August included downside guidance and a near-term customer spend warning.&nbsp;</li><li>               Applied Materials shares are&nbsp;<font color='red'>down 1%&nbsp;</font>premarket to $39.23. Shares are&nbsp;<font color='red'>down 17.4%</font>&nbsp;in the quarter and&nbsp;<font color='red'>22.5%</font>&nbsp;YTD.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3388402-semi-stocks-slip-analysts-question-micron\" target=\"_blank\">Semi stocks slip after analysts question Micron</a> (Sept. 6)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3389740-semi-stocks-slide-goldman-downgrades\" target=\"_blank\">Semi stocks slide on Goldman downgrades</a> (Sept. 12)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3383656-amat-minus-3_5-percent-q3-report-downside-guide-near-term-customer-spend-warning\" target=\"_blank\">AMAT -3.5% on Q3 report with downside guide, near-term customer spend warning</a> (Aug. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3392375\" data-linked=\"Citi removes Applied Materials from its Focus List\" data-tweet=\"$AMAT - Citi removes Applied Materials from its Focus List https://seekingalpha.com/news/3392375-citi-removes-applied-materials-from-focus-list?source=tweet\" data-url=\"https://seekingalpha.com/news/3392375-citi-removes-applied-materials-from-focus-list\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3392372\" data-ts=\"1537793093\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3392372-rbc-presents-amd-bull-case-reports-of-sell-side-firm-questioning-share-gain\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RBC presents AMD bull case; reports of sell-side firm questioning share gain</a></h4><ul><li>RBC Capital starts AMD (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>) at Outperform and a $40 price target with an upside to $60.</li><li>Firm is positive on AMD on server growth, gaming demand, and margin expansion.</li><li>RBC outlines a bull case for $2+ 2021E EPS.</li><li>On the other side, Notable Calls reports hearing a sell-side firm saying it has found zero evidence of AMD achieving incremental share gains in servers.</li><li>Sources: StreetAccount/<a href=\"https://twitter.com/thenotablecalls\" target=\"_blank\">Notable Calls</a>.</li><li>AMD shares are&nbsp;<font color='green'>up 0.1%</font>&nbsp;premarket to $31.04.</li><li>        Update with <a href=\"https://www.cnbc.com/2018/09/24/rbc-predicts-nearly-30percent-gain-for-amd-notable-discount-to-nvidia.html\" target=\"_blank\">more color</a> from RBC:</li><li>               Analyst Mitch Steves cites steady demand for gaming chips and solid gains in the server market and says that while AMD will remain volatile, it trades at a &ldquo;notable discount on a sales basis relative to peer Nvidia (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>).&rdquo;&nbsp;</li><li>               Steves calls AMD&rsquo;s latest graphics processor &ldquo;competitive&rdquo; and expects the second-gen to &ldquo;surpass Intel (NASDAQ:<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a>) from a performance vs. cost basis.&rdquo;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3392372\" data-linked=\"RBC presents AMD bull case; reports of sell-side firm questioning share gain\" data-tweet=\"$AMD $AMD $NVDA - RBC presents AMD bull case; reports of sell-side firm questioning share gain https://seekingalpha.com/news/3392372-rbc-presents-amd-bull-case-reports-of-sell-side-firm-questioning-share-gain?source=tweet\" data-url=\"https://seekingalpha.com/news/3392372-rbc-presents-amd-bull-case-reports-of-sell-side-firm-questioning-share-gain\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>99&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}